var title_f23_10_23712="Pulmonary angioscope";
var content_f23_10_23712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Pulmonary angioscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fiberoptic pulmonary angioscope allows intraluminal visualization of the pulmonary arteries to the segmental level.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter F Fedullo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23712=[""].join("\n");
var outline_f23_10_23712=null;
var title_f23_10_23713="Age and stroke rate";
var content_f23_10_23713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F64724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F64724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Age and stroke rate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 436px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Number of patients according to age and age-specific occurrence rates per 100,000.",
"    <div class=\"footnotes\">",
"     R: correlation coefficient of the trend line illustrating the exponential increase in occurrence as a function of age.",
"     <br>",
"      * P&lt;0.001 in comparison of age-specific proportions between genders by Chi-Sq test.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Putaala, J, Metso, AJ, Metso, TM, et al. Stroke: The Helsinki Young Stroke Registry Analysis of 1008 Consecutive Patients Aged 15 to 49 With First-Ever Ischemic Stroke: The Helsinki Young Stroke Registry. Stroke 2009; 40:1195. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23713=[""].join("\n");
var outline_f23_10_23713=null;
var title_f23_10_23714="Patient information: Hodgkin lymphoma in adults (The Basics)";
var content_f23_10_23714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15858\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/6/25702\">",
"         Lymphatic system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/50/31523\">",
"         Patient information: Hodgkin lymphoma in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/28/40386\">",
"         Patient information: Lymphoma (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/37/13908\">",
"         Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hodgkin lymphoma in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hodgkin-lymphoma-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6934012\">",
"      <span class=\"h1\">",
"       What is Hodgkin lymphoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hodgkin lymphoma is a type of lymphoma. Lymphoma is a cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make and store cells that fight infection (",
"      <a class=\"graphic graphic_figure graphicRef63854 \" href=\"UTD.htm?25/6/25702\">",
"       figure 1",
"      </a>",
"      ). These infection-fighting cells are also called &ldquo;white blood cells.&rdquo;",
"     </p>",
"     <p>",
"      When people have lymphoma, their white blood cells become abnormal, grow out of control, and travel to different parts of the body. The abnormal cells often collect in bean-shaped organs called lymph nodes. This causes the lymph nodes to swell.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6934019\">",
"      <span class=\"h1\">",
"       What are the symptoms of Hodgkin lymphoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with Hodgkin lymphoma first notice a swollen, painless lymph node in the neck. People can also have swollen lymph nodes above the collar bone, or in the armpit or groin.",
"     </p>",
"     <p>",
"      Lymph nodes deeper in the body can become swollen and cause symptoms. For example, swollen lymph nodes in the chest can cause a cough, trouble breathing, or chest pain.",
"     </p>",
"     <p>",
"      Some people can also have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Night sweats that soak their clothes",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6934026\">",
"      <span class=\"h1\">",
"       Is there a test for Hodgkin lymphoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will talk with you and do an exam. He or she will also do:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A lymph node biopsy &ndash; A doctor will remove 1 of the swollen lymph nodes. Then another doctor will look at the cells under a microscope to see if cancer cells are present.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6934033\">",
"      <span class=\"h1\">",
"       What is lymphoma staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lymphoma staging is a way in which doctors find out how far the lymphoma has spread in the lymphatic system or in the body.",
"     </p>",
"     <p>",
"      Hodgkin lymphoma usually starts in lymph nodes in the neck or chest. If the cancer spreads, it usually spreads to nearby lymph nodes, and then to organs such as the spleen or liver.",
"     </p>",
"     <p>",
"      To check how far your Hodgkin lymphoma has spread, your doctor will do an exam, blood tests, and an imaging test, such as a CT or PET scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p>",
"      Your doctor might also do a bone marrow biopsy. For this test, a doctor will take a small sample of bone marrow (the tissue in the middle of your bones). Another doctor will look at the sample under a microscope to see if it has cancer.",
"     </p>",
"     <p>",
"      The right treatment for you depends a lot on the stage of your Hodgkin lymphoma.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6934040\">",
"      <span class=\"h1\">",
"       How is Hodgkin lymphoma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. Doctors can use different chemotherapy medicines to treat Hodgkin lymphoma. Your doctor will work with you to choose the ones that are right for you.",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People whose Hodgkin lymphoma doesn&rsquo;t get better with treatment or comes back after treatment might have a bone marrow transplant. This treatment replaces cells in the bone marrow that are killed by chemotherapy or radiation.",
"     </p>",
"     <p>",
"      Most of the time, Hodgkin lymphoma can be cured with treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6934047\">",
"      <span class=\"h1\">",
"       What else should I know about treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some treatments for Hodgkin lymphoma can increase a person&rsquo;s chance of getting another type of cancer in the future. For example, women who get radiation therapy to the chest can have an increased chance of getting breast cancer years later. Talk with your doctor about what you can do to check for or prevent other cancers in the future.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6934054\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for Hodgkin lymphoma involves making many choices, such as what treatment to have and when.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6934061\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/28/40386?source=see_link\">",
"       Patient information: Lymphoma (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/50/31523?source=see_link\">",
"       Patient information: Hodgkin lymphoma in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=see_link\">",
"       Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/10/23714?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15858 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23714=[""].join("\n");
var outline_f23_10_23714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6934012\">",
"      What is Hodgkin lymphoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6934019\">",
"      What are the symptoms of Hodgkin lymphoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6934026\">",
"      Is there a test for Hodgkin lymphoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6934033\">",
"      What is lymphoma staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6934040\">",
"      How is Hodgkin lymphoma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6934047\">",
"      What else should I know about treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6934054\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6934061\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15858\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/6/25702\">",
"      Lymphatic system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/50/31523?source=related_link\">",
"      Patient information: Hodgkin lymphoma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/28/40386?source=related_link\">",
"      Patient information: Lymphoma (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_10_23715="Anatomic landmarks during direct laryngoscopy";
var content_f23_10_23715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomic landmarks during direct laryngoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 608px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomic landmarks for direct laryngoscopy. A) After initial retraction of the tongue with a straight blade, the epiglottis may remain draped posteriorly, partially or completely covering the glottic opening. B) Retraction of the epiglottis with the tip of the straight blade allows visualization of the glottis and surrounding structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: King C, Rappaport LD. Emergent endotracheal intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23715=[""].join("\n");
var outline_f23_10_23715=null;
var title_f23_10_23716="Linear IgA bullous dermatosis on face";
var content_f23_10_23716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Linear IgA bullous dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple tense vesicles are present on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23716=[""].join("\n");
var outline_f23_10_23716=null;
var title_f23_10_23717="Bosutinib: Patient drug information";
var content_f23_10_23717=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bosutinib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     see \"Bosutinib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15367319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bosulif&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F15034592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15034594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15034593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3896103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bosutinib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15034598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant, do not handle crushed or broken tablets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15034599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697877",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count. This drug may need to be stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15034600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15034596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695929",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15034597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424379",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is less than 12 hours until the next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15034601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15034602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86615 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-42756325B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23717=[""].join("\n");
var outline_f23_10_23717=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15367319\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034592\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034594\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034593\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034598\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034599\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034600\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034596\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034597\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034601\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15034602\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=related_link\">",
"      Bosutinib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_10_23718="Stingray envenomation";
var content_f23_10_23718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stingray envenomation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 549px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The stingrays of the",
"    <em>",
"     Dasyatis",
"    </em>",
"    genus are the most common marine stingrays.",
"    <br>",
"     (B) Note the serrated barb.",
"     <br>",
"      (C) A severe sting with total perforation of the foot of a fisherman.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced from: Haddad V, Lupi O, Lonza JP, Tyring SK. Tropical dermatology: marine and aquatic dermatology. J Am Acad Derm 2009; 61:733. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23718=[""].join("\n");
var outline_f23_10_23718=null;
var title_f23_10_23719="Pathogenesis of the Raynaud phenomenon";
var content_f23_10_23719=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of the Raynaud phenomenon",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/10/23719/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/10/23719/contributors\">",
"     Fredrick M Wigley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/10/23719/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/10/23719/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/10/23719/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/10/23719/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/10/23719/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the normal physiologic responses to cold temperature is the lowering of blood flow to the skin, thereby reducing the loss of body heat and preserving normal core temperature. Blood flow to the skin is regulated by a complex interactive system involving neural signals, circulating hormones, and mediators released from both circulating cells and blood vessels.",
"   </p>",
"   <p>",
"    The Raynaud phenomenon (RP) is an exaggerated vascular response to cold temperature or emotional stress. The phenomenon is manifested clinically by sharply demarcated color changes of the skin of the digits. Abnormal vasoconstriction of digital arteries and cutaneous arterioles due to a local defect in normal vascular responses is thought to underlie the primary form of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RP is considered primary if these symptoms occur alone without evidence of any associated disorder. By comparison, secondary disease refers to the presence of RP in association with a related illness, such as systemic lupus erythematosus and systemic sclerosis (SSc).",
"   </p>",
"   <p>",
"    The pathogenesis of RP will be reviewed here. The definition, clinical manifestations, diagnosis, and treatment of the disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link\">",
"     \"Initial treatment of the Raynaud phenomenon\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maurice Raynaud in 1862 stated that \"local asphyxia of the extremities\" was a result of \"increased irritability of the central parts of the cord presiding over the vascular innervation\" [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/4\">",
"     4",
"    </a>",
"    ]. In 1930, after observing that even when reflex vasodilation is produced by warming the body, vasospasm could still be induced by putting the hands in cold water, and conversely, that vasospasm could not be produced by body cooling if the hands were kept warm, Sir Thomas Lewis concluded that RP was due to a \"local fault\" rather than a defect in the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/5\">",
"     5",
"    </a>",
"    ]. Currently, a local defect(s) is hypothesized to be responsible for RP. However, the exact abnormality may vary depending upon the underlying cause [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In primary RP, evidence suggests the defect is an increase in alpha-2 adrenergic responses in the digital and cutaneous vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In secondary RP, the defect may vary depending upon the underlying insult to the normal physiology of the digital and cutaneous arteries. Many diseases, disorders, drugs, and environmental exposures have been associated with secondary RP (",
"      <a class=\"graphic graphic_table graphicRef77253 \" href=\"UTD.htm?30/50/31532\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20098589\">",
"    <span class=\"h1\">",
"     NORMAL SENSORY SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temperature perception is a critical function of the somatosensory system that protects us from extreme thermal conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/7\">",
"     7",
"    </a>",
"    ]. Afferent nerve fibers of the somatosensory system detect environmental stimuli and in cold temperatures activate both A&delta;- and unmyelinated C-fibers. Temperature-sensitive ion channels on specialized dorsal root ganglion neurons allow cutaneous nerves to respond to both heat and cold. A cold receptor, Transient Receptor Potential ion channel (TRPM8), is responsible for detection of various degrees of cold temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/8\">",
"     8",
"    </a>",
"    ]. These primary afferent neurons convert thermal stimuli into action potentials that relay sensory information to the spinal cord and brain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While TRPM8 neurons are a molecularly diverse population, a direct association with a defect or unique subtype in these receptors causing Raynaud&rsquo;s has not been shown. The",
"    <span class=\"nowrap\">",
"     preoptical/anterior",
"    </span>",
"    hypothalamus in the brain is now known to act as a &ldquo;thermostat,&rdquo; receiving information from peripheral signals and coordinating efferent responses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/10\">",
"     10",
"    </a>",
"    ]. Sympathetic mediated vasoconstrictor and vasodilator nerves innervate arterioles and regulate regional blood flow in the skin. An increase in blood flow allows heat to dissipate, while a decrease in cutaneous blood flow preserves body heat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20098618\">",
"    <span class=\"h2\">",
"     Role of neuropeptides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like the endothelium, nerve endings sense the microenvironment and release factors that contribute to the balance between vasodilation and vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/11\">",
"     11",
"    </a>",
"    ]. The peripheral nervous system releases vasodilating (substance P, vasoactive intestinal peptide, calcitonin gene-related peptide, neurokinin A) and vasoconstricting (somatostatin, neuropeptide Y) neuropeptides. The sympathetic nervous system is the major mediator of vasoconstriction in the skin via release of norepinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NORMAL VESSEL REACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of blood vessel reactivity is a complex interactive system involving neural signals, circulating hormones, and mediators released from cells and the blood vessel. This process can be disrupted or perturbed at several potential sites, but the clinical manifestations of RP may be the final expression of abnormal reactivity of the terminal arteries. During local or whole body cooling, blood flow to the skin is reduced to prevent heat loss. This response to cold is mediated by reflex activation of the sympathetic nervous system and by a direct effect of cold on cutaneous blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/13\">",
"     13",
"    </a>",
"    ]. Thermoregulation is further accomplished by numerous arteriovenous anastomoses (AVA), low resistance conduits that allow shunting of blood from arterioles to venules at high flow rates.",
"   </p>",
"   <p>",
"    Normal vascular smooth muscle of different arteries have variable degrees of inherent contractile activity (phasic and tonic), which range from relatively high activity (such as the coronary circulation), to low or absent (such as the pulmonary circulation). This inherent activity can be dramatically increased following activation of the vascular smooth muscle cell by vasoconstrictor agonists or by changes in the local environment of the cell (as in response to an increase in transmural pressure, called autoregulation). On the other hand, vasodilator agonists or local environmental changes (ischemia) can dramatically reduce myogenic activity. Cold activates vasoconstriction by selectively amplifying vascular smooth muscle constriction to the sympathetic neurotransmitter, norepinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/12\">",
"     12",
"    </a>",
"    ]. The vasoconstriction depends on local activation of adrenergic nerves and an increase in number and affinity of the postsynaptic alpha-2 receptors on cutaneous vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of endothelial cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although vascular smooth muscle can respond directly to circulating hormones or environmental stimuli, important physiologic control of smooth muscle activity is indirectly mediated by endothelial cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11785?source=see_link\">",
"     \"The coronary microcirculation in disease states\"",
"    </a>",
"    .) Endothelium-derived nitric oxide (NO) contributes to this protective action by inhibiting vascular smooth muscle contraction, proliferation, and migration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. NO also inhibits platelet aggregation, stimulates platelet disaggregation, and inhibits the adhesion of platelets, lymphocytes and neutrophils to the endothelial surface [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endothelial cells also release prostaglandins that are vasodilatory (prostacyclin) and endothelin-1 that is a potent vasoconstrictor. Both prostacyclin and endothelin are thought to affect vascular remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of intravascular factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular reactivity is also affected by shear stress, vasoactive substances released during platelet activation (thromboxane, serotonin), changes in blood viscosity and potentially by changes in rheological properties of blood such as altered red blood cell deformability. Function of the fibrinolytic system appears to be normal in primary Raynaud's phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/18\">",
"     18",
"    </a>",
"    ]. &nbsp;Estrogen may have a role as a mediator of changes in vascular tone. Epidemiological studies suggest that estrogen use is associated with RP, but the biological evidence demonstrates that estrogens may act as vasodilators [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/19\">",
"     19",
"    </a>",
"    ]. Studies addressing endothelial function and vasomotor changes in patients with RP showed that acute and chronic estrogen administration has some positive effect on flow-mediated dilation of the brachial artery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PRIMARY RP",
"    </span>",
"    &nbsp;&mdash;&nbsp;In primary RP, there is compelling evidence that the increased sensitivity to cold temperatures is mediated in part by abnormal alpha-adrenergic responses, particularly mediated by alpha-2 receptors. In normal subjects, the alpha receptors are increased in the small arteries, particularly in the cutaneous arteries and veins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, the administration of \"selective\" alpha-1 and alpha-2 adrenergic agonists to human volunteers causes a marked reduction in skin or finger blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with primary RP, the pathogenic importance of alpha-2 receptors is suggested by experiments with selective receptor antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. In one report of 23 patients, for example, the number of fingers with cold-induced vasospastic attacks was markedly reduced with yohimbine (an alpha-2 receptor blocker) compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"     prazosin",
"    </a>",
"    (an alpha-1 receptor blocker) &mdash; 0.3 versus 2.3 fingers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The analysis of responses to exogenous administration of agonists has not provided a clear answer to the underlying reason for the increased cold sensitivity of alpha-2 receptors in primary RP. In different studies, the responses to \"selective\" alpha-2 adrenergic agonists were either increased or unchanged in patients with RP when compared to controls, and responses to \"selective\" alpha-1 adrenergic agonists were either not changed, increased or decreased in affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different subtypes of alpha-2 receptors (alpha 2A, 2B, and 2C) display differing sensitivity to cold. Experiments using isolated murine tail artery revealed that the alpha 2C subtype is responsible for the thermoregulatory function of the alpha -2 receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/29\">",
"     29",
"    </a>",
"    ]. This suggests that an altered pattern of expression of these alpha 2 subtypes could modify alpha-2 receptor sensitivity during cold exposure, but not at normal temperatures.",
"   </p>",
"   <p>",
"    Alpha 2C-adrenoreceptors play a prominent role in vasoconstriction of cutaneous arteries after moderate cooling [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/30\">",
"     30",
"    </a>",
"    ]. Under normal conditions (37&ordm;C) alpha 2C-adrenoreceptors are \"silently\" stored within the Golgi apparatus. They translocate to the cell surface after cold exposure and contribute to the adrenergic constrictive response. Cooling induces activation of",
"    <span class=\"nowrap\">",
"     Rho/Rho",
"    </span>",
"    kinase signaling pathway and this prompts translocation of alpha 2C-adrenoreceptors from the Golgi complex to the plasma membrane together with augmented sensitivity to Ca++ of contractile proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial trigger for",
"    <span class=\"nowrap\">",
"     Rho/Rho",
"    </span>",
"    kinase signaling may be provided by a rapid increase of reactive oxygen species (ROS) in smooth muscle cells following cold exposure (28&ordm;C) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/32\">",
"     32",
"    </a>",
"    ]. This is a relevant observation, since Raynaud vasospastic attacks may initiate a cycle of ischemia and reperfusion with further production of ROS, subsequent activation of",
"    <span class=\"nowrap\">",
"     Rho/Rho",
"    </span>",
"    kinase pathway thus provoking repeated episodes of vasospasm.",
"   </p>",
"   <p>",
"    Increased contractile responses to alpha 2-adrenergic agonists and cooling observed in patients with RP compared to healthy controls is associated with increased protein tyrosine kinase (PTK) activity and tyrosine phosphorylation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. These abnormalities are described in arteries from both primary (PRP) and secondary RP (SRP) subjects, providing a theoretical unifying explanation for the cold-induced vascular reactivity.",
"   </p>",
"   <p>",
"    Other possibilities for the increased cold sensitivity of alpha-2 receptors in primary RP may be unrelated to a direct alteration in alpha receptor expression. These include increased production of endothelin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/35\">",
"     35",
"    </a>",
"    ], decreased sensory nerve innervation (CGRP-containing nerve fibers) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/36\">",
"     36",
"    </a>",
"    ], and impaired dilator function of the endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/37\">",
"     37",
"    </a>",
"    ]. However, subsequent studies have failed to demonstrate altered activity of endothelin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], of endothelial dilator activity in primary RP [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/39\">",
"     39",
"    </a>",
"    ], or increased activity of 5-hydroxytryptamine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/25\">",
"     25",
"    </a>",
"    ]. Cold-induced cutaneous vasoconstriction is also restrained by simultaneous cold-induced vasodilation, thus a defect in the regulation of sympathetic-induced vasodilation could lead to excessive vasoconstriction. Vascular disease is generally associated with a decreased protective role of the endothelium and diminished activity of nitric oxide (NO) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/14\">",
"     14",
"    </a>",
"    ]. The decreased activity of NO may then contribute to worsening vasoconstriction. Among the complex mechanisms that regulate vascular tone, there may more than one responsible for the excessive vasoconstriction seen clinically as an attack of RP.",
"   </p>",
"   <p>",
"    Based upon the studies demonstrating increased sensitivity of alpha-2 receptors, it is unlikely that nonadrenergic mechanisms alone contribute to cold-induced vasospasm in primary RP. However, nonadrenergic mechanisms could act indirectly to selectively modulate the alpha-2 adrenergic response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional insight into the underlying mechanism of primary RP may be derived via the study of patients who belong to families in which the disease is clustered [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. As an example, a genome-wide screen among such families tentatively identified five genetic loci (on the X chromosome and chromosomes 6, 7, 9, and 17) that may be linked with the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SECONDARY RP",
"    </span>",
"    &nbsp;&mdash;&nbsp;In secondary forms of RP, it is thought that the underlying vascular disease disrupts the normal mechanisms responsible for control of vessel reactivity. In systemic sclerosis (scleroderma), for example, unique changes in the microvascular system develop in association with intimal fibrosis and endothelial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/45\">",
"     45",
"    </a>",
"    ]. The endothelial cell damage or dysfunction appears to occur at an early stage, and is associated with increased platelet adhesion, decreased storage of von Willebrand factor, and decreased adenosine uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/18,46-50\">",
"     18,46-50",
"    </a>",
"    ]. Increased activity of reactive oxygen species (ROS) that follows ischemic reperfusion injury may then alter smooth muscle receptor expression and vascular function [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, not all increased vascular reactivity can be attributed to problems with endothelial function or fibrosis in patients with SSc. As an example, a selective increase in alpha-2 adrenergic receptor reactivity may occur in the arterioles of sclerodermatous skin in the absence of demonstrable endothelial cell dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other changes have been demonstrated including: enhanced endothelial cell thymidine labeling, suggesting the presence of endothelial injury and repair [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/53\">",
"     53",
"    </a>",
"    ], increased circulating levels of endothelin-1 and reduced activity of NO [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/54-56\">",
"     54-56",
"    </a>",
"    ], and increased expression of endothelin receptors in microvessels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23719/abstract/37,55\">",
"     37,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/63/19450?source=see_link\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30481?source=see_link\">",
"       \"Patient information: Raynaud phenomenon (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95777458\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temperature perception is a critical function of the somatosensory system that protects us from extreme thermal conditions. Afferent nerve fibers of the somatosensory system detect environmental stimuli and, in cold temperatures, activate both A&delta;- and unmyelinated C-fibers. Temperature-sensitive ion channels on specialized dorsal root ganglion neurons allow cutaneous nerves to respond to both heat and cold. Like the endothelium, nerve endings sense the microenvironment and release factors that contribute to the balance between vasodilation and vasoconstriction. (See",
"      <a class=\"local\" href=\"#H20098589\">",
"       'Normal sensory system'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20098618\">",
"       'Role of neuropeptides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Control of blood vessel reactivity is a complex interactive system involving neural signals, circulating hormones, and mediators released from cells and the blood vessel. This process can be disrupted or perturbed at several potential sites, but the clinical manifestations of RP may be the final expression of abnormal reactivity of the terminal arteries. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Normal vessel reactivity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although vascular smooth muscle can respond directly to circulating hormones or to environmental stimuli, important physiologic control of smooth muscle activity is indirectly mediated by endothelial cells. Vascular reactivity is also affected by shear stress, by vasoactive substances released during platelet activation (thromboxane, serotonin), by changes in blood viscosity, and, potentially, by changes in rheological properties of blood such as altered red blood cell deformability. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Role of endothelial cells'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Role of intravascular factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Raynaud phenomenon (RP) is an exaggerated vascular response to cold temperature or emotional stress. Abnormal vasoconstriction of digital arteries and cutaneous arterioles due to a local defect in normal vascular responses is thought to underlie the primary form of this disorder. In primary RP, evidence suggests the defect is an increase in alpha-2 adrenergic responses in the digital and cutaneous vessels. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Primary RP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In secondary RP, the defect may vary depending upon the underlying insult to the normal physiology of the digital and cutaneous arteries. Many diseases, disorders, drugs, and environmental exposures have been associated with secondary RP (",
"      <a class=\"graphic graphic_table graphicRef77253 \" href=\"UTD.htm?30/50/31532\">",
"       table 1",
"      </a>",
"      ). In secondary forms of RP, it is thought that the underlying vascular disease disrupts the normal mechanisms responsible for control of vessel reactivity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Secondary RP'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/1\">",
"      Boin F, Wigley FM. Understanding, assessing and treating Raynaud's phenomenon. Curr Opin Rheumatol 2005; 17:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/2\">",
"      Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001; 357:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/3\">",
"      Wigley FM. Clinical practice. Raynaud's Phenomenon. N Engl J Med 2002; 347:1001.",
"     </a>",
"    </li>",
"    <li>",
"     Raynaud, M. Local asphyxia and symmetrical gangrene of the extremities 1862. New researches on the nature and treatment of local asphyxia of the extremities 1874. Translated by Barlow London: New Syndenham Society,1888.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/5\">",
"      Lewis T. Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation of the fingers. A variety of Raynaud's disease. Heart 1929; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/6\">",
"      Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 2005; 44:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/7\">",
"      McKemy DD. How cold is it? TRPM8 and TRPA1 in the molecular logic of cold sensation. Mol Pain 2005; 1:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/8\">",
"      Schepers RJ, Ringkamp M. Thermoreceptors and thermosensitive afferents. Neurosci Biobehav Rev 2010; 34:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/9\">",
"      McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002; 416:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/10\">",
"      Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc 2003; 78:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/11\">",
"      Generini S, Seibold JR, Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud's phenomenon. Rheum Dis Clin North Am 2005; 31:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/12\">",
"      Flavahan NA, Vanhoutte PM. Effect of cooling on alpha-1 and alpha-2 adrenergic responses in canine saphenous and femoral veins. J Pharmacol Exp Ther 1986; 238:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/13\">",
"      Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003; 29:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/14\">",
"      Flavahan NA, Vanhoutte PM. Endothelial cell signaling and endothelial dysfunction. Am J Hypertens 1995; 8:28S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/15\">",
"      Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/16\">",
"      Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/17\">",
"      Kirchengast M, M&uuml;nter K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med 1999; 221:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/18\">",
"      Herrick AL, Illingworth K, Blann A, et al. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996; 55:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/19\">",
"      Fraenkel L, Zhang Y, Chaisson CE, et al. The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med 1998; 129:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/20\">",
"      Lekakis J, Papamichael C, Mavrikakis M, et al. Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. Am J Cardiol 1998; 82:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/21\">",
"      Lekakis J, Mavrikakis M, Papamichael C, et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Am Heart J 1998; 136:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/22\">",
"      Flavahan NA, Cooke JP, Shepherd JT, Vanhoutte PM. Human postjunctional alpha-1 and alpha-2 adrenoceptors: differential distribution in arteries of the limbs. J Pharmacol Exp Ther 1987; 241:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/23\">",
"      Coffman JD, Cohen RA. Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits. Eur J Clin Invest 1988; 18:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/24\">",
"      Ekenvall L, Lindblad LE, Norbeck O, Etzell BM. alpha-Adrenoceptors and cold-induced vasoconstriction in human finger skin. Am J Physiol 1988; 255:H1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/25\">",
"      Coffman JD, Cohen RA. Alpha-2-adrenergic and 5-HT2 receptor hypersensitivity in Raynaud's disease. J Vasc Med Biol 1990; 2:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/26\">",
"      Freedman RR, Baer RP, Mayes MD. Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease. Circulation 1995; 92:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/27\">",
"      Freedman RR, Moten M, Mig&aacute;ly P, Mayes M. Cold-induced potentiation of alpha 2-adrenergic vasoconstriction in primary Raynaud's disease. Arthritis Rheum 1993; 36:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/28\">",
"      Lindblad LE, Ekenvall L, Etzell BM, Beveg&aring;rd S. Adrenoceptors in Raynaud's disease. J Cardiovasc Pharmacol 1989; 14:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/29\">",
"      Chotani MA, Flavahan S, Mitra S, et al. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000; 278:H1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/30\">",
"      Chotani MA, Mitra S, Su BY, et al. Regulation of alpha(2)-adrenoceptors in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2004; 286:H59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/31\">",
"      Bailey SR, Eid AH, Mitra S, et al. Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ Res 2004; 94:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/32\">",
"      Bailey SR, Mitra S, Flavahan S, Flavahan NA. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol 2005; 289:H243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/33\">",
"      Furspan PB, Chatterjee S, Mayes MD, Freedman RR. Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon. Rheumatology (Oxford) 2005; 44:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/34\">",
"      Furspan PB, Chatterjee S, Freedman RR. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum 2004; 50:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/35\">",
"      Zamora MR, O'Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990; 336:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/36\">",
"      Bunker CB, Terenghi G, Springall DR, et al. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 1990; 336:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/37\">",
"      Knock GA, Terenghi G, Bunker CB, et al. Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis. J Invest Dermatol 1993; 101:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/38\">",
"      Bottomley W, Goodfield M. A pathogenic role for endothelin in Raynaud's phenomenon? Acta Derm Venereol 1994; 74:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/39\">",
"      Khan F, Coffman JD. Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon. Circulation 1994; 89:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/40\">",
"      de Trafford JC, Lafferty K, Potter CE, et al. An epidemiological survey of Raynaud's phenomenon. Eur J Vasc Surg 1988; 2:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/41\">",
"      Planchon B, Pistorius MA, Beurrier P, De Faucal P. Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients. Angiology 1994; 45:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/42\">",
"      Freedman RR, Mayes MD. Familial aggregation of primary Raynaud's disease. Arthritis Rheum 1996; 39:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/43\">",
"      MacGregor AJ, Cherkas LJ, Carter L, et al. The genetic contribution to Raynaud's phenomenon: a population-based twin study. Arthritis Rheum 1999; 42:S233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/44\">",
"      Susol E, MacGregor AJ, Barrett JH, et al. A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon. Arthritis Rheum 2000; 43:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/45\">",
"      Wigley FM. Vascular disease in scleroderma. Clin Rev Allergy Immunol 2009; 36:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/46\">",
"      Blann AD, Illingworth K, Jayson MI. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol 1993; 20:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/47\">",
"      Freemont AJ, Hoyland J, Fielding P, et al. Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br J Dermatol 1992; 126:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/48\">",
"      Kazandjian S, Fiessinger JN, Camilleri JP, et al. Endothelial cell renewal in skin of patients with progressive systemic sclerosis (PSS): an in vitro autoradiographic study. Acta Derm Venereol 1982; 62:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/49\">",
"      Pearson JD. The endothelium: its role in scleroderma. Ann Rheum Dis 1991; 50 Suppl 4:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/50\">",
"      Prescott RJ, Freemont AJ, Jones CJ, et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992; 166:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/51\">",
"      Matucci Cerinic M, Kahaleh MB. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology (Oxford) 2002; 41:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/52\">",
"      Flavahan NA, Flavahan S, Liu Q, et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000; 43:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/53\">",
"      Fleischmajer R, Perlish JS. [3H]Thymidine labeling of dermal endothelial cells in scleroderma. J Invest Dermatol 1977; 69:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/54\">",
"      Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991; 34:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/55\">",
"      Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994; 21:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23719/abstract/56\">",
"      Freedman RR, Girgis R, Mayes MD. Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma. Lancet 1999; 354:739.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7553 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-93025ABAAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23719=[""].join("\n");
var outline_f23_10_23719=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H95777458\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20098589\">",
"      NORMAL SENSORY SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20098618\">",
"      Role of neuropeptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NORMAL VESSEL REACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of endothelial cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of intravascular factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PRIMARY RP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SECONDARY RP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95777458\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7553\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7553|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/50/31532\" title=\"table 1\">",
"      Factors associated with Raynauds",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=related_link\">",
"      Initial treatment of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/63/19450?source=related_link\">",
"      Pathogenesis of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30481?source=related_link\">",
"      Patient information: Raynaud phenomenon (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11785?source=related_link\">",
"      The coronary microcirculation in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=related_link\">",
"      Treatment of the Raynaud phenomenon resistant to initial therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_10_23720="Anatomic location VSD";
var content_f23_10_23720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Anatomic locations of ventricular septal defects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: The ventricular septum, viewed from the right ventricular side (left panel), is made up of four components: the inlet (I) extends from the tricupid annulus to attachments of the tricuspid valve; the trabecular septum (T) extends from inlet out to apex and up to smooth-walled outlet; the outlet (O) or infundibular septum extends up to the pulmonary valve; and the membranous septum. Right panel: The anatomic location of ventricular septal defects.",
"    <div class=\"footnotes\">",
"     a: outlet defect; b: papillary muscle of the conus; c: perimembranous defect; d: marginal muscular defects; e: central muscular defects; f: inlet defect; g: apical muscular defects.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Graham, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23720=[""].join("\n");
var outline_f23_10_23720=null;
var title_f23_10_23721="Anaplastic thyroid cancer";
var content_f23_10_23721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anaplastic thyroid cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/10/23721/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/10/23721/contributors\">",
"     R Michael Tuttle, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/10/23721/contributors\">",
"     Eric J Sherman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/10/23721/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/10/23721/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/10/23721/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/10/23721/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/10/23721/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/10/23721/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaplastic thyroid cancers are undifferentiated tumors of the thyroid follicular epithelium. In marked contrast to differentiated thyroid cancers, anaplastic cancers are extremely aggressive, with a disease-specific mortality approaching 100 percent. Given the very rapid course of disease progression and the poor treatment outcomes, end of life issues and plans for comfort care measures are an integral part of initial disease management planning [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/1\">",
"     1",
"    </a>",
"    ]. Early recognition of the disease is essential to allow prompt initiation of therapy.",
"   </p>",
"   <p>",
"    The major clinical issues related to anaplastic thyroid cancer will be reviewed here. The molecular pathogenesis of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=see_link\">",
"     \"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age-adjusted annual incidence of anaplastic cancer is about one to two per million persons [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/2-4\">",
"     2-4",
"    </a>",
"    ], and accounts for 0.9 to 9.8 percent of all thyroid cancers globally [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Patients with anaplastic cancer are older than those with differentiated cancer; the mean age at diagnosis is 65 years and fewer than 10 percent are younger than 50 years. Sixty to 70 percent of tumors occur in women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTECEDENT THYROID DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of patients with anaplastic thyroid cancer have a history of differentiated thyroid cancer, and 20 to 30 percent have a coexisting differentiated cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]; the percentage may be even higher with extensive sectioning of the thyroid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/14\">",
"     14",
"    </a>",
"    ]. The majority of synchronous thyroid tumors are papillary cancers, but coexisting follicular cancers have also been reported. Nearly 10 percent of patients with H&uuml;rthle-cell cancers have foci of anaplastic cancer within the H&uuml;rthle-cell cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, transformation from differentiated to anaplastic cancer has been described in a patient who was followed with serial biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings lend support to the hypothesis that anaplastic cancer develops from more differentiated tumors as a result of one or more dedifferentiating events [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/17\">",
"     17",
"    </a>",
"    ]. Since activating mutations in BRAF and RAS are seen in both well differentiated thyroid malignancies and anaplastic thyroid cancer, these are presumed to be early events in the progression pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/18\">",
"     18",
"    </a>",
"    ]. Late events that are seen more commonly in the anaplastic tumor rather than the precursor well differentiated tumor include mutations in p53 tumor suppressor protein [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/19-22\">",
"     19-22",
"    </a>",
"    ], 16p [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/23\">",
"     23",
"    </a>",
"    ], catenin (cadherin-associated protein), beta 1, and PIK3CA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Up to one-half of patients have a history of multinodular goiter and some have a history of partial thyroidectomy for goiter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2187194\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Disease presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all patients with anaplastic cancer present with a thyroid mass. However, regional or distant spread is apparent at the time of initial diagnosis in 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/12-14,25\">",
"     12-14,25",
"    </a>",
"    ]. Sites of regional involvement can include the perithyroidal fat and muscle, lymph nodes, larynx, trachea, esophagus, tonsil, and great vessels of the neck and mediastinum. Distant metastases are found at initial disease presentation in 15 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/9-11,13\">",
"     9-11,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lungs are the most common site of distant metastases, being involved in up to 90 percent of patients with distant disease [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. These metastases are usually intrapulmonary mass lesions, but pleural involvement can occur.",
"     </li>",
"     <li>",
"      Approximately 5 to 15 percent of patients have bone metastases.",
"     </li>",
"     <li>",
"      Five percent have brain metastases, and a few have metastases to the skin, liver, kidneys, pancreas, heart, and adrenal glands [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/10-12,26-30\">",
"       10-12,26-30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rare patients have no detectable thyroid tumor at the time of diagnosis, presenting with metastatic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary symptom of anaplastic cancer is a rapidly enlarging neck mass, occurring in about 85 percent of patients. The enlarging thyroid tumor may cause neck pain and tenderness, and compression (or invasion) of the upper aerodigestive tract, resulting in dyspnea (about 35 percent of patients), dysphagia (30 percent), hoarseness (25 percent), cough (and sometimes hemoptysis, 25 percent). Less common symptoms are chest pain, bone pain, headache, confusion, or abdominal pain from metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/26,31\">",
"     26,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Constitutional symptoms can occur, including anorexia, weight loss, fatigue, and fever of unknown origin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Rarely, rapid growth of the tumor within the thyroid causes thyroiditis, with symptoms of hyperthyroidism and more severe neck pain and tenderness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/26,35,36\">",
"     26,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On physical examination, most patients have bilateral but asymmetric thyroid enlargement. The goiter is typically hard and nodular, and may be tender. A dominant nodule is often present. Some nodules may be softer and fluctuant, indicating focal tumor necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/14\">",
"     14",
"    </a>",
"    ]. A few patients have a solitary nodule or a diffuse non-nodular goiter. The goiter is often fixed to the surrounding structures and does not move with swallowing. By the time of presentation, the primary tumor is usually greater than 5 cm in diameter, but exact measurements are often difficult because the borders of the tumor are indistinct.",
"   </p>",
"   <p>",
"    Approximately 50 percent of patients have enlarged cervical lymph nodes. Other findings of local extension of the disease include stridor, tracheal deviation, and vocal cord paralysis due to compression or invasion of the trachea, and venous dilatation and superior vena cava syndrome due to retrosternal tumor growth.",
"   </p>",
"   <p>",
"    The skin overlying the tumor may be erythematous or even ulcerated, and there may be metastases in the skin of the chest and abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/14,37\">",
"     14,37",
"    </a>",
"    ]. Focal neurologic symptoms or signs suggesting brain metastases may also be present.",
"   </p>",
"   <p>",
"    Most patients have normal serum thyroid hormone and thyrotropin (TSH) concentrations, except for those few patients with tumor-related thyroiditis and hyperthyroidism from presumed rapid tumor growth and concomitant tissue destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/26,35,36\">",
"     26,35,36",
"    </a>",
"    ]. Serum thyroglobulin concentrations may be high, most often due to secretion from a coexisting differentiated cancer, rather than the anaplastic cancer. Rare patients have leukocytosis due to tumor secretion of lymphokines [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings on thyroid ultrasound are not specific for anaplastic thyroid cancer. Ultrasonography cannot distinguish benign from malignant intrathyroidal tumors (both tend to be hypoechoic). However detection of extrathyroidal invasion can provide support for the diagnosis of cancer. Ultrasonography of the neck also can accurately identify involvement of local and regional nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\", section on 'Criteria for identifying cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of anaplastic cancer is usually established by cytologic examination of cells obtained by fine needle aspiration biopsy or of tissue obtained by large needle or surgical biopsy. Ultrasonography can be used to guide fine needle aspiration of solid, non-necrotic tumor. In a series of 113 fine needle aspirates in patients with anaplastic thyroid cancer, 107 (94.7 percent) were diagnostic of malignancy, and 96 of 107 were diagnosed as anaplastic thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/40\">",
"     40",
"    </a>",
"    ]. The remaining 11 were diagnosed as differentiated thyroid cancer and malignant tumor not otherwise specified. Large needle (core) or surgical biopsy is typically performed when the fine needle aspiration shows necrotic or inflamed tissue without a specific diagnosis. Evaluation of the biopsy material should include routine light microscopy and analysis with immunohistochemistry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31814?source=see_link\">",
"     \"Ultrasound-guided thyroid biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On cytopathology, morphologic patterns of anaplastic thyroid cancer include spindle cell, pleomorphic giant cell,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    squamoid [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/10\">",
"     10",
"    </a>",
"    ]. Many anaplastic thyroid cancers have a mixed morphology of two or all three patterns. One common mixed morphologic type is biphasic spindle and giant cell tumor (",
"    <a class=\"graphic graphic_picture graphicRef88833 \" href=\"UTD.htm?28/12/28869\">",
"     picture 1",
"    </a>",
"    ). Numerous mitotic figures and atypical mitoses are present (",
"    <a class=\"graphic graphic_picture graphicRef88832 \" href=\"UTD.htm?2/28/2505\">",
"     picture 2",
"    </a>",
"    ). There is typically extensive necrosis. Unlike differentiated thyroid cancer, anaplastic thyroid cancer cells are much less likely to stain positive for thyroid transcription factor-1 (TTF1) or PAX-8 and do not stain positive for thyroglobulin in the anaplastic component of the tumor (may see thyroglobulin staining in the associated more well differentiated component of the tumor) (",
"    <a class=\"graphic graphic_table graphicRef88072 \" href=\"UTD.htm?33/0/33805\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29674060\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other malignancies that may look histologically similar to anaplastic thyroid cancer but have significantly different treatment and prognosis include poorly differentiated thyroid cancer, medullary thyroid cancer, lymphoma, melanoma, and sarcoma. Differentiation of anaplastic and poorly differentiated thyroid cancer may be difficult in some patients with anaplastic thyroid cancer who have coexisting poorly differentiated (or well differentiated) thyroid cancer. Careful attention to morphology and immunohistochemical studies (",
"    <a class=\"graphic graphic_table graphicRef88072 \" href=\"UTD.htm?33/0/33805\">",
"     table 1",
"    </a>",
"    ) is required to distinguish anaplastic thyroid cancer from poorly differentiated thyroid cancer and other malignancies.",
"   </p>",
"   <p>",
"    The differential diagnosis in a patient presenting with a neck mass is extensive and varies with the age of the patient at presentation. Although the majority of these masses represent benign thyroid nodules and cysts or differentiated thyroid cancer, a rapidly growing neck mass is concerning for anaplastic thyroid cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    .) Neck masses that are not of thyroidal origin may be congenital (ie, vascular anomaly), inflammatory (lymph node enlargement), or other neoplastic (primary or metastatic disease) disorders. The differential diagnosis of a neck mass is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11608?source=see_link\">",
"     \"Differential diagnosis of a neck mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2187238\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients diagnosed with anaplastic thyroid cancer on the basis of the findings on cytopathology, evaluation should include laboratory evaluation and imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6357864\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically measure thyroid function tests (TSH, free T4), if not previously measured, complete blood count, electrolytes, BUN, creatinine, glucose, and liver function tests. We also measure serum calcium and phosphorus to assess for hypercalcemia of malignancy or hypocalcemia due to compromise of the parathyroid glands secondary to invading anaplastic thyroid cancer. Since anaplastic thyroid cancer often arises in a setting of a more well differentiated thyroid cancer, we measure serum thyroglobulin as part of the initial evaluation to assess for the possibility of metastatic well differentiated thyroid cancer and to assist in determining if the metastatic lesions are from the well differentiated component of the tumor (rather than anaplastic metastatic sites), recognizing that elevated serum thyroglobulin can also be seen in nodular thyroid disease and goiter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate imaging is critical for defining the extent of disease, planning therapy, and monitoring the response to treatment. Consistent with the recommendations from the American Thyroid Association guidelines for the management of patients with anaplastic thyroid cancer, we typically obtain ultrasound of the neck (if not already performed), positron emission tomography (PET) using 18 F-fluorodeoxyglucose (neck to pelvis), and brain MRI (or CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/41\">",
"     41",
"    </a>",
"    ]. If PET scanning is not readily available, cross sectional imaging of the brain, neck, chest, abdomen and pelvis with CT or MRI provides adequate initial staging information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PET scan is being used with increasing frequency to evaluate and monitor patients with anaplastic thyroid cancer. In patients with anaplastic thyroid cancer, there is intense uptake of 18FDG in the primary thyroid tumor, cervical and mediastinal lymph nodes, and in distant metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/42-45\">",
"       42-45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Computed tomography (CT) of the neck and mediastinum can accurately delineate the extent of the thyroid tumor and identify tumor invasion of the great vessels and upper aerodigestive tract [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/46\">",
"       46",
"      </a>",
"      ]. Typical findings include masses that are isodense or slightly hyperdense relative to skeletal muscle, dense calcifications, and areas of necrosis. MRI is similarly useful for defining the local extent of disease and for identifying distant metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with bony metastases, skeletal radiographs typically show lytic lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3574001\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because 20 to 30 percent of patients with anaplastic thyroid cancer have coexisting differentiated thyroid cancer, the presence of metastases does not automatically indicate that they originate from anaplastic thyroid cancer. The serum thyroglobulin level",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PET scan may help distinguish between the two. In patients with metastatic differentiated thyroid cancer, the thyroglobulin level is markedly elevated, whereas it should be normal in patients with anaplastic thyroid cancer. In addition, compared with metastases from differentiated thyroid cancer, metastases from anaplastic thyroid cancer are hypermetabolic and have more avid uptake on PET scanning. Rarely, fine needle biopsy of distant metastatic sites is required to differentiate anaplastic from differentiated thyroid cancer. In patients with surgically resectable disease, biopsy of distant metastases can be performed after completion of primary surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6358271\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with anaplastic thyroid cancer who present with a rapidly growing neck mass and voice hoarseness require evaluation by an",
"    <span class=\"nowrap\">",
"     otolaryngologist/head",
"    </span>",
"    and neck surgeon to assess for vocal cord function, airway invasion, and resectability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3574110\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;All anaplastic cancers are considered stage IV cancers. Intrathyroidal anaplastic cancers are designated IVA (T4a), whereas anaplastic cancers with gross extrathyroidal extension are IVB (T4b) and with distant metastases IVC (",
"    <a class=\"graphic graphic_table graphicRef73748 \" href=\"UTD.htm?1/45/1758\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few randomized trials assessing treatment strategies for anaplastic thyroid cancer. The following approach, which is largely consistent with the American Thyroid Association guideline for management of patients with anaplastic thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/41\">",
"     41",
"    </a>",
"    ], is based upon case series and clinical expertise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tumor localized to the thyroid or locally advanced operable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who present with resectable tumors, we suggest complete resection followed by combined radiotherapy and chemotherapy. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Combined modality therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is often not indicated because the disease is advanced at the time of diagnosis in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/49\">",
"     49",
"    </a>",
"    ]. However, if the tumor appears localized to the thyroid, or if locoregional disease is resectable, complete resection should be attempted, as long as gross tumor resection can be achieved with minimal morbidity. After complete resection, some patients have prolonged survival (&gt;2 years), often in conjunction with postoperative adjuvant therapy (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Impact of adjuvant therapy'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/7,12,50,51\">",
"     7,12,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the rare patients with intrathyroidal tumors, without a co-existent well differentiated thyroid cancer component, thyroid lobectomy with wide margins of adjacent soft tissue on the side of the tumor is an appropriately aggressive surgical approach [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/9\">",
"     9",
"    </a>",
"    ]. As long as the tumor is small and confined entirely to the thyroid, total thyroidectomy with complete tumor resection does not prolong survival compared with ipsilateral thyroid lobectomy, and is associated with a higher complication rate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. Nevertheless, some experts prefer total or near total thyroidectomy with central and lateral neck lymph node dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/41\">",
"     41",
"    </a>",
"    ]. The rational for this is that differentiated thyroid cancer and anaplastic thyroid cancer often coexist, and total thyroidectomy offers a greater chance of complete resection. For patients with a small intrathyroidal anaplastic cancer associated with a differentiated thyroid cancer, we favor total thyroidectomy, if it can be done with complete gross resection of tumor and minimal morbidity, to facilitate subsequent treatment of the differentiated cancer.",
"   </p>",
"   <p>",
"    For patients with locally advanced disease, the extent of surgery depends upon the degree of soft tissue involvement. Options include total thyroidectomy, lobectomy with wide margins of adjacent soft tissue, or en bloc resection. If complete en bloc resection (sparing the larynx) can be achieved with minimal morbidity, it should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Impact of adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of the Surveillance, Epidemiology, and End Results database found surgery and external beam radiotherapy improved survival for patients with disease extending into adjacent tissues who did not have distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/52\">",
"     52",
"    </a>",
"    ]; the efficacy of adjuvant radiotherapy after surgery is supported by other uncontrolled observations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/7,53,54\">",
"     7,53,54",
"    </a>",
"    ]. Multiple reports support a possible survival advantage for combined modality therapy combining radiation and chemotherapy, although selection bias is a major confounding factor in determining the effect of treatment on outcome. Patients who undergo resection followed by adjuvant therapy often have less extensive disease. The optimal timing of the individual components and the selection of chemotherapy regimen are uncertain (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Combined modality therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1275800\">",
"    <span class=\"h2\">",
"     Locally advanced inoperable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who present with locally advanced inoperable disease who desire active therapy (rather than palliative care), we suggest combined radiotherapy and chemotherapy for local control of disease (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Combined modality therapy'",
"    </a>",
"    below). Surgical resection for residual tumor could be considered if the disease is responsive [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/50,55\">",
"     50,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam radiotherapy, administered in conventional doses, does",
"    <strong>",
"     not",
"    </strong>",
"    prolong survival when administered for advanced disease. Although up to 80 percent of patients may initially respond to radiation, most have local recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with locally advanced disease, hyperfractionated radiotherapy, combined with radiosensitizing doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , may increase the local response rate to about 80 percent, with subsequent median survival of one year; distant metastases then become the leading cause of death. Similar improvement in local disease control has been reported with the combination of preoperative or neoadjuvant hyperfractionated radiotherapy and doxorubicin, followed by debulking surgery in responsive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperfractionated accelerated radiation therapy alone using \"radical\" doses (&gt;40 Gy) may improve local control when compared with lower dose palliative radiotherapy (&le;40 Gy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39191?source=see_link&amp;anchor=H7#H7\">",
"     \"External beam radiotherapy in the treatment of thyroid cancer\", section on 'Anaplastic thyroid cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase II study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    versus",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"     /doxorubicin",
"    </span>",
"    in patients with advanced thyroid cancer, 39 subjects with anaplastic thyroid cancer were included [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/56\">",
"     56",
"    </a>",
"    ]. Among these patients, there were six (34 percent) responses in the",
"    <span class=\"nowrap\">",
"     cisplatin/doxorubicin",
"    </span>",
"    arm (three complete, three partial response), whereas there was only one (5 percent) response (partial) in the doxorubicin alone arm. Two of the three subjects with a complete response remained without evidence of disease 34 and 41 months after starting treatment.",
"   </p>",
"   <p>",
"    The highest response rate (50 percent) with a single-agent chemotherapy agent was reported in a single phase II study (20 patients) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/57\">",
"     57",
"    </a>",
"    ]. However, this high response rate has not been confirmed in any subsequent phase II or III studies.",
"   </p>",
"   <p>",
"    Overall, the response duration for any agent is generally short and long-term survival (as well as local control in the neck) probably unaffected. Several drugs, such as vascular disrupting agents and receptor tyrosine kinase inhibitors, are actively being studied.",
"   </p>",
"   <p>",
"    BRAF and p53 mutations are common in anaplastic thyroid cancer and may be interesting targets for future investigations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=see_link&amp;anchor=H15#H15\">",
"     \"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer\", section on 'Anaplastic thyroid cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Combined modality therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several uncontrolled studies have evaluated various chemotherapy regimens concurrently with radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/55,58-60\">",
"     55,58-60",
"    </a>",
"    ]. Most studies use a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based regimen. In one study, 37 patients were treated with weekly doxorubicin (10",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    with hyperfractionated radiation therapy (given three days per week) for a median total dose of 5760 cGy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/61\">",
"     61",
"    </a>",
"    ]. Median survival was six months with 28 percent alive at one year. The median locoregional progression-free survival was 10.1 months. Elderly patients (&ge;70 years) had worse outcomes than younger patients, with 60 percent dying in the first three months. Another study evaluated a more intensive regimen combining surgery (if possible) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (120",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    and doxorubicin (60",
"    <span class=\"nowrap\">",
"     mg/m2),",
"    </span>",
"    both before and after hyperfractionated radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/55\">",
"     55",
"    </a>",
"    ]. For 30 patients, median survival was 10 months, and three-year survival was 27 percent.",
"   </p>",
"   <p>",
"    Randomized controlled trials are not available to definitively prove benefit for combined modality therapy. Thus, there are no standard regimens. However, the use of weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    concurrently with radiation therapy is both reasonable and commonly applied [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/61\">",
"     61",
"    </a>",
"    ], while more aggressive regimens have combined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and doxorubicin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/60\">",
"     60",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and doxorubicin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/55\">",
"     55",
"    </a>",
"    ] with radiation. Given the overall poor prognosis of current treatment modalities, consideration should always be given to referring a patient with anaplastic cancer for participation in a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1275641\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no effective therapy for metastatic anaplastic thyroid cancer, and the disease is uniformly fatal. In one case series, the median survival in patients with anaplastic thyroid cancer with distant metastases at the time of initial diagnosis was 4.2 months compared with six months in those without metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/62\">",
"     62",
"    </a>",
"    ]. In patients with advanced disease, palliation of symptoms is a high priority [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/41\">",
"     41",
"    </a>",
"    ]. Locoregional resection may be necessary for palliation of airway or esophageal obstruction. However, death is usually attributable to upper airway obstruction and suffocation (often despite tracheostomy) in 50 to 60 percent of patients, and to a combination of complications of local and distant disease in the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/12,63\">",
"     12,63",
"    </a>",
"    ]. For patients with bone metastases, palliative radiotherapy may be beneficial in improving pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87068624\">",
"    <span class=\"h2\">",
"     Radioactive iodine scanning and therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioactive iodine (RAI) has no role in the primary treatment of anaplastic thyroid cancer. However, RAI",
"    <span class=\"nowrap\">",
"     scanning/ablation/therapy",
"    </span>",
"    should be considered in survivors, one to two years after initial therapy, if a significant component of the original tumor was well differentiated or if the serum thyroglobulin level remains inappropriately elevated during follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=see_link\">",
"     \"Radioiodine treatment of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6211702\">",
"    <span class=\"h2\">",
"     End of life care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the very rapid course of disease progression and the poor treatment outcomes, end of life issues and plans for comfort care measures are an integral part of initial disease management planning [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/41\">",
"     41",
"    </a>",
"    ]. Palliative and end of life care issues are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link\">",
"     \"Approach to symptom assessment in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12890?source=see_link\">",
"     \"Pain assessment and management in the last weeks of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=see_link\">",
"     \"Overview of managing common non-pain symptoms in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3575237\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who respond to initial management require surveillance for recurrence. We typically obtain CT scan (brain, neck, chest, abdomen, pelvis) every one to three months for the first 6 to 12 months, and then less frequently (every four to six months) thereafter. In patients with no clinical evidence of disease on CT scan, PET scan may show disease recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, we also obtain PET imaging three to six months after initial therapy (in patients with no disease on CT). Other imaging studies should be based upon clinical symptoms that develop during follow-up.",
"   </p>",
"   <p>",
"    Patients who have total thyroidectomy require thyroid hormone therapy to replace normal thyroid hormone production. Thyroxine (T4, approximately 1.6",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    of body weight) should be started immediately after surgery. The adequacy of therapy should be evaluated clinically and by measurement of serum thyrotropin (TSH) in one month. The goal of T4 therapy should be to restore and maintain euthyroidism; suppression of serum TSH concentrations to less than normal is not indicated, unless for treatment of coexisting differentiated thyroid cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link&amp;anchor=H18#H18\">",
"     \"Surgical treatment of differentiated thyroid cancer\", section on 'Postoperative thyroid hormone therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2187296\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaplastic thyroid cancers are extremely aggressive, with a disease-specific mortality approaching 100 percent. The median survival from diagnosis ranges from three to seven months, and the one- and five-year survival rates are 20 to 35 percent and 5 to 14 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/12,13,25,50,53,64,65\">",
"     12,13,25,50,53,64,65",
"    </a>",
"    ], although many feel that these estimates are overly optimistic. In a review of published case series (1771 patients treated between 1949 and 2007), the median survival was five months, and the one-year survival was 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/5\">",
"     5",
"    </a>",
"    ]. Several important prognostic characteristics have been identified. Patients with disease either confined to the thyroid or with only local and regional metastases survive longer than those with distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/7,9,11,66\">",
"     7,9,11,66",
"    </a>",
"    ]. Tumor size also appears to be important. In one study, as an example, the two-year survival was 25 versus 3 to 15 percent in patients with tumors less than 6 cm versus larger than 6 cm in maximum dimension [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/9,12\">",
"     9,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other variables that may predict a worse prognosis include older age at diagnosis, male sex, and dyspnea as a presenting symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/7,9-12,53,54,66\">",
"     7,9-12,53,54,66",
"    </a>",
"    ]. Patients who were previously treated for differentiated cancer and subsequently developed anaplastic cancer have outcomes similar to those without an antecedent cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23721/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relatively favorable prognostic factors include unilateral tumor, diameter of less than 5 cm, and the absence of extrathyroidal invasion or cervical lymph node involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaplastic thyroid cancer is almost always rapidly fatal, the few exceptions being patients whose tumors are small and who are treated very aggressively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 20 percent of patients have a history of differentiated thyroid cancer and 20 to 30 percent have a coexisting differentiated cancer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antecedent thyroid disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary symptom of anaplastic cancer is a rapidly enlarging neck mass, occurring in about 85 percent of patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of anaplastic cancer is usually established by cytologic examination of cells obtained by fine needle aspiration biopsy or of tissue obtained by large needle or surgical biopsy. Evaluation of the biopsy material should include routine light microscopy and analysis with immunohistochemistry (",
"      <a class=\"graphic graphic_table graphicRef88072 \" href=\"UTD.htm?33/0/33805\">",
"       table 1",
"      </a>",
"      ). On cytopathology, morphologic patterns of anaplastic thyroid cancer include spindle cell, pleomorphic giant cell,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      squamoid (",
"      <a class=\"graphic graphic_picture graphicRef88833 \" href=\"UTD.htm?28/12/28869\">",
"       picture 1",
"      </a>",
"      ). Many anaplastic thyroid cancers have a mixed morphology of two or all three patterns. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other malignancies that may look histologically similar to anaplastic thyroid cancer but have significantly different treatment and prognosis include poorly differentiated thyroid cancer, medullary thyroid cancer, lymphoma, melanoma, and sarcoma. Careful attention to morphology and immunohistochemical studies (",
"      <a class=\"graphic graphic_table graphicRef88072 \" href=\"UTD.htm?33/0/33805\">",
"       table 1",
"      </a>",
"      ) are required to distinguish anaplastic thyroid cancer from poorly differentiated thyroid cancer and other malignancies. (See",
"      <a class=\"local\" href=\"#H29674060\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients diagnosed with anaplastic thyroid cancer on the basis of the findings on cytopathology, evaluation should include laboratory (TSH, free T4, thyroglobulin, complete blood count, electrolytes, BUN, creatinine, glucose, liver function tests, calcium, and phosphorus) and imaging studies. Initial imaging to determine extent of disease should include ultrasound of the neck (if not already performed), positron emission tomography (PET) using 18 F-fluorodeoxyglucose (neck to pelvis), and brain MRI (or CT). If PET scanning is not readily available, cross-sectional imaging of the brain, neck, chest, abdomen, and pelvis with CT or MRI provides adequate initial staging information. (See",
"      <a class=\"local\" href=\"#H2187238\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a small intrathyroidal anaplastic cancer associated with a differentiated thyroid cancer, we suggest total thyroidectomy (if it can be done with complete gross resection of tumor and minimal morbidity) rather than lobectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Total thyroidectomy will facilitate subsequent treatment of the differentiated thyroid cancer. However, for the rare patients with intrathyroidal anaplastic thyroid cancer, without a co-existent well differentiated thyroid cancer component, thyroid lobectomy with wide margins of adjacent soft tissue on the side of the tumor is an appropriately aggressive alternative surgical approach. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with locally advanced operative disease, we also suggest surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The extent of surgery depends upon the degree of soft tissue involvement. Options include total thyroidectomy, lobectomy with wide margins of adjacent soft tissue, or en bloc resection. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those patients whose tumors are resected completely, we suggest postoperative combined modality therapy with radiation and chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Chemotherapy options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and doxorubicin. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Impact of adjuvant therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Combined modality therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Because of the lack of effective standard of care treatments, enrollment in clinical trials is strongly encouraged when available.",
"     </li>",
"     <li>",
"      For patients who present with locally advanced inoperable disease, we suggest combined radiotherapy and chemotherapy for local control of disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Chemotherapy options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and doxorubicin. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Combined modality therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Radiotherapy alone using doses &gt;40 Gy may also be effective for local control in patients with high performance status. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39191?source=see_link&amp;anchor=H7#H7\">",
"       \"External beam radiotherapy in the treatment of thyroid cancer\", section on 'Anaplastic thyroid cancer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with metastatic disease, treatment should be directed toward securing the airway and ensuring access for nutritional support. If the patient has a good performance status, enrollment in clinical trials is strongly encouraged when available. (See",
"      <a class=\"local\" href=\"#H1275641\">",
"       'Metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Palliative/comfort",
"      </span>",
"      care should be an integral part of initial treatment planning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link\">",
"       \"Palliative care: Benefits, services, and models of care\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28490?source=see_link\">",
"       \"Overview of comprehensive patient assessment in palliative care\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=see_link\">",
"       \"Approach to symptom assessment in palliative care\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12890?source=see_link\">",
"       \"Pain assessment and management in the last weeks of life\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=see_link\">",
"       \"Overview of managing common non-pain symptoms in palliative care\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/1\">",
"      Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008; 37:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/2\">",
"      Akslen LA, Haldorsen T, Thoresen SO, Glattre E. Incidence of thyroid cancer in Norway 1970-1985. Population review on time trend, sex, age, histological type and tumour stage in 2625 cases. APMIS 1990; 98:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/3\">",
"      Burke JP, Hay ID, Dignan F, et al. Long-term trends in thyroid carcinoma: a population-based study in Olmsted County, Minnesota, 1935-1999. Mayo Clin Proc 2005; 80:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/4\">",
"      Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/5\">",
"      Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 2010; 22:486.",
"     </a>",
"    </li>",
"    <li>",
"     SEER Cancer Statistics Review 1975-2009. file://seer.cancer.gov/csr/1975_2009_pops09/results_merged/sect_26_thyroid.pdf (Accessed on February 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/7\">",
"      Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005; 103:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/8\">",
"      Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011; 2011:542358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/9\">",
"      Nel CJ, van Heerden JA, Goellner JR, et al. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc 1985; 60:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/10\">",
"      Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 1985; 83:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/11\">",
"      Venkatesh YS, Ordonez NG, Schultz PN, et al. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990; 66:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/12\">",
"      Tan RK, Finley RK 3rd, Driscoll D, et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995; 17:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/13\">",
"      McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001; 130:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/14\">",
"      Aldinger KA, Samaan NA, Ibanez M, Hill CS Jr. Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid. Cancer 1978; 41:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/15\">",
"      Chiu, AC, Oliveira, AA, Schultz, PN, Ordonez, NG, Sherman, SI. Prognostic clinicopathologic features in H&uuml;rthle cell neoplasia. Thyroid 1996; 6:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/16\">",
"      Moore JH Jr, Bacharach B, Choi HY. Anaplastic transformation of metastatic follicular carcinoma of the thyroid. J Surg Oncol 1985; 29:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/17\">",
"      Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009; 69:4885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/18\">",
"      Quiros RM, Ding HG, Gattuso P, et al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 2005; 103:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/19\">",
"      Nakamura T, Yana I, Kobayashi T, et al. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 1992; 83:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/20\">",
"      Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992; 52:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/21\">",
"      Ito T, Seyama T, Mizuno T, et al. Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Jpn J Cancer Res 1993; 84:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/22\">",
"      Moretti F, Farsetti A, Soddu S, et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1997; 14:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/23\">",
"      Komoike Y, Tamaki Y, Sakita I, et al. Comparative genomic hybridization defines frequent loss on 16p in human anaplastic thyroid carcinoma. Int J Oncol 1999; 14:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/24\">",
"      Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009; 16:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/25\">",
"      Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002; 86:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/26\">",
"      Nishiyama RH, Dunn EL, Thompson NW. Anaplastic spindle-cell and giant-cell tumors of the thyroid gland. Cancer 1972; 30:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/27\">",
"      Hadar T, Mor C, Har-El G, Sidi J. Anaplastic thyroid carcinoma metastatic to the tonsil. J Laryngol Otol 1987; 101:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/28\">",
"      Phillips DL, Benner KG, Keeffe EB, Traweek ST. Isolated metastasis to small bowel from anaplastic thyroid carcinoma. With a review of extra-abdominal malignancies that spread to the bowel. J Clin Gastroenterol 1987; 9:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/29\">",
"      Murabe H, Akamizu T, Kubota A, Kusaka S. Anaplastic thyroid carcinoma with prominent cardiac metastasis, accompanied by a marked leukocytosis with a neutrophilia and high GM-CSF level in serum. Intern Med 1992; 31:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/30\">",
"      Hadar T, Mor C, Shvero J, et al. Anaplastic carcinoma of the thyroid. Eur J Surg Oncol 1993; 19:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/31\">",
"      Lip GY, Jaap AJ, McCruden DC. A presentation of anaplastic carcinoma of the thyroid with symptomatic intra-abdominal metastases. Br J Clin Pract 1992; 46:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/32\">",
"      Glikson M, Feigin RD, Libson E, Rubinow A. Anaplastic thyroid carcinoma in a retrosternal goiter presenting as fever of unknown origin. Am J Med 1990; 88:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/33\">",
"      Hanslik T, Gepner P, Franc B, et al. [Anaplastic cancer of the thyroid gland disclosed by prolonged fever or hyperleukocytosis. Two cases]. Ann Med Interne (Paris) 1996; 147:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/34\">",
"      Chang TC, Liaw KY, Kuo SH, et al. Anaplastic thyroid carcinoma: review of 24 cases, with emphasis on cytodiagnosis and leukocytosis. Taiwan Yi Xue Hui Za Zhi 1989; 88:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/35\">",
"      Murakami T, Noguchi S, Murakami N, et al. Destructive thyrotoxicosis in a patient with anaplastic thyroid cancer. Endocrinol Jpn 1989; 36:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/36\">",
"      Oppenheim A, Miller M, Anderson GH Jr, et al. Anaplastic thyroid cancer presenting with hyperthyroidism. Am J Med 1983; 75:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/37\">",
"      Barr R, Dann F. Anaplastic thyroid carcinoma metastatic to skin. J Cutan Pathol 1974; 1:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/38\">",
"      Fujita T, Ogasawara Y, Naito M, et al. Anaplastic thyroid carcinoma associated with granulocyte colony-stimulating factor: report of a case. Surg Today 2006; 36:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/39\">",
"      Sato T, Omura M, Saito J, et al. Neutrophilia associated with anaplastic carcinoma of the thyroid: production of macrophage colony-stimulating factor (M-CSF) and interleukin-6. Thyroid 2000; 10:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/40\">",
"      Us-Krasovec M, Golouh R, Auersperg M, et al. Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol 1996; 40:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/41\">",
"      Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012; 22:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/42\">",
"      Bogsrud TV, Karantanis D, Nathan MA, et al. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid 2008; 18:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/43\">",
"      Poisson T, Deandreis D, Leboulleux S, et al. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/44\">",
"      Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control 2005; 12:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/45\">",
"      Nguyen BD, Ram PC. PET/CT staging and posttherapeutic monitoring of anaplastic thyroid carcinoma. Clin Nucl Med 2007; 32:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/46\">",
"      Takashima S, Morimoto S, Ikezoe J, et al. CT evaluation of anaplastic thyroid carcinoma. AJR Am J Roentgenol 1990; 154:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/47\">",
"      Miyakoshi A, Dalley RW, Anzai Y. Magnetic resonance imaging of thyroid cancer. Top Magn Reson Imaging 2007; 18:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/48\">",
"      Chiacchio S, Lorenzoni A, Boni G, et al. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol 2008; 33:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/49\">",
"      Sherman SI. Thyroid carcinoma. Lancet 2003; 361:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/50\">",
"      Haigh PI, Ituarte PH, Wu HS, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001; 91:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/51\">",
"      Swaak-Kragten AT, de Wilt JH, Schmitz PI, et al. Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. Radiother Oncol 2009; 92:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/52\">",
"      Chen J, Tward JD, Shrieve DC, Hitchcock YJ. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol 2008; 31:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/53\">",
"      Pierie JP, Muzikansky A, Gaz RD, et al. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 2002; 9:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/54\">",
"      Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992; 18:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/55\">",
"      De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/56\">",
"      Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/57\">",
"      Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000; 10:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/58\">",
"      Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987; 60:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/59\">",
"      Troch M, Koperek O, Scheuba C, et al. High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab 2010; 95:E54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/60\">",
"      Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011; 21:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/61\">",
"      Sherman EJ, Lim SH, Ho AL, et al. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol 2011; 101:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/62\">",
"      Ito K, Hanamura T, Murayama K, et al. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck 2012; 34:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/63\">",
"      Tallroth E, Wallin G, Lundell G, et al. Multimodality treatment in anaplastic giant cell thyroid carcinoma. Cancer 1987; 60:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/64\">",
"      Spires JR, Schwartz MR, Miller RH. Anaplastic thyroid carcinoma. Association with differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 1988; 114:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/65\">",
"      Sherman, SI, Brierley, J, Sperling, M, Maxon III, HR. Initial analysis of staging and outcomes from a prospective multicenter study of treatment of thyroid carcinoma. Thyroid 1996; 6:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23721/abstract/66\">",
"      Akslen LA, Haldorsen T, Thoresen SO, Glattre E. Survival and causes of death in thyroid cancer: a population-based study of 2479 cases from Norway. Cancer Res 1991; 51:1234.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2189 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23721=[""].join("\n");
var outline_f23_10_23721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTECEDENT THYROID DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2187194\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Disease presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29674060\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2187238\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6357864\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3574001\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6358271\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3574110\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tumor localized to the thyroid or locally advanced operable disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Impact of adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1275800\">",
"      Locally advanced inoperable disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Combined modality therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1275641\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87068624\">",
"      Radioactive iodine scanning and therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6211702\">",
"      End of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3575237\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2187296\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2189\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2189|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/12/28869\" title=\"picture 1\">",
"      Anaplastic thyroid cancer 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/28/2505\" title=\"picture 2\">",
"      Anaplastic thyroid cancer 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2189|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/0/33805\" title=\"table 1\">",
"      Immunohistochemical markers dx ATC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/45/1758\" title=\"table 2\">",
"      TNM staging thyroid cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41178?source=related_link\">",
"      Approach to symptom assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11608?source=related_link\">",
"      Differential diagnosis of a neck mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39191?source=related_link\">",
"      External beam radiotherapy in the treatment of thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=related_link\">",
"      Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28490?source=related_link\">",
"      Overview of comprehensive patient assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/37/12890?source=related_link\">",
"      Pain assessment and management in the last weeks of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=related_link\">",
"      Radioiodine treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=related_link\">",
"      Surgical treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31814?source=related_link\">",
"      Ultrasound-guided thyroid biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_10_23722="Clinical manifestations and diagnosis of amyloid cardiomyopathy";
var content_f23_10_23722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/10/23722/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/10/23722/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/10/23722/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/10/23722/contributors\">",
"     Rodney H Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/10/23722/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/10/23722/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/10/23722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/10/23722/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/10/23722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloidosis refers to the extracellular deposition of fibrils that are composed of low molecular weight subunits (5 to 25 kD) of a variety of serum proteins. These fibrils adopt a beta-pleated sheet configuration that leads to characteristic histologic changes. Amyloid deposits can occur in a variety of organs, with involvement of the heart, kidney, liver, and autonomic nervous system most often being responsible for morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link\">",
"     \"An overview of amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of cardiac involvement varies among types of amyloidosis. The prognosis of amyloid cardiomyopathy also varies among types of amyloidosis, with high mortality rates, particularly in light&ndash;chain (AL) amyloidosis.",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations and diagnosis of amyloid cardiomyopathy. The prognosis and treatment of amyloid cardiomyopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23958?source=see_link\">",
"     \"Treatment of amyloid cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165325929\">",
"    <span class=\"h1\">",
"     TYPES OF AMYLOIDOSIS THAT MAY INVOLVE THE HEART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although over 25 different amyloidogenic proteins have been described, many are rare and some do not affect the heart. The three most common types of amyloidosis, defined by their precursor proteins, are AL, ATTR, and AA amyloidosis. The frequency and severity of cardiac involvement varies among various types of amyloidosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In AL (primary) amyloidosis, a plasma cell dyscrasia, the amyloid protein consists of a monoclonal light chain. Clinical evidence of cardiac involvement occurs in up to 50 percent of patients with AL amyloidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/1\">",
"       1",
"      </a>",
"      ] compared to less than 5 percent with AA amyloidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"       \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In AL amyloidosis there is evidence that the biochemical characteristics of the light chain may be important as illustrated by the following observations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In an experimental model using isolated mouse hearts, infusion of light chains from patients with AL amyloidosis who had severe cardiac involvement markedly impaired ventricular relaxation without affecting systolic function [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/3\">",
"       3",
"      </a>",
"      ]. In comparison, there was no change in diastolic function with infusion of light chains from patients with no or mild cardiac involvement or from patients with multiple myeloma.",
"     </li>",
"     <li>",
"      In a study in isolated cardiac myocytes, light chains from patients with cardiac amyloidosis caused an increase in oxidant stress with alteration of the cellular redox state; these biochemical changes were associated with impairment in myocyte contractility and relaxation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In ATTR amyloidosis, the amyloid protein consists of wild-type (non-mutant) or mutated transthyretin (TTR, previously called prealbumin). Transthyretin (TTR) is a small protein tetramer that is almost exclusively produced in the liver.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Wild-type (non-mutated) transthyretin is responsible for senile systemic amyloidosis, the predominant feature of which is an infiltrative cardiomyopathy.",
"     </li>",
"     <li>",
"      Mutations in the gene for TTR are often associated with amyloid cardiomyopathy. In transthyretin-associated amyloidosis due to a mutation in the transthyretin molecule (ATTR), the presence of cardiac involvement varies with the specific mutation (of which over 100 have been described) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/5\">",
"       5",
"      </a>",
"      ]. Some mutations are invariably associated with cardiac disease, others usually only with neurologic disease, and many have a combination of both. Mutant TTR is the main cause of familial amyloid cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=see_link&amp;anchor=H3#H3\">",
"       \"Genetic factors in the amyloid diseases\", section on 'Transthyretin'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H27260123\">",
"       'ATTR cardiac amyloidosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fragments of serum amyloid A protein, an acute phase reactant, are responsible for AA (secondary) amyloidosis, which is associated with a variety of chronic inflammatory disorders. However, AA amyloidosis rarely produces clinically apparent heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=see_link\">",
"       \"Pathogenesis of secondary (AA) amyloidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical cardiac amyloidosis is uncommon in the rare forms of familial amyloidosis not due to transthyretin mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2009885\">",
"    <span class=\"h2\">",
"     General manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid cardiomyopathy most commonly manifests as heart failure, characterized by dyspnea and edema. Angina, presyncope, and syncope may occasionally be the presenting features [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/8\">",
"     8",
"    </a>",
"    ]. Non-specific symptoms, often due to involvement of other organs (most commonly occurring in AL amyloidosis) include poor appetite, early satiety, and weight loss. Low cardiac output may also contribute to renal dysfunction, which in AL amyloidosis may already have been compromised by amyloid deposition in the kidneys.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2728666\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms and signs of heart failure include dyspnea and signs of right-sided heart failure including peripheral edema, hepatomegaly, and ascites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link\">",
"     \"Evaluation of the patient with heart failure or cardiomyopathy\"",
"    </a>",
"    .) Although left heart pressures are elevated, pulmonary edema is rare. As demonstrated by necropsy studies as well as clinical imaging studies, the ventricular walls are typically thickened with normal left ventricular cavity size, normal-sized or mildly dilated right ventricular cavity, and biatrial enlargement.",
"   </p>",
"   <p>",
"    An uncommon presentation is disproportionate amyloid accumulation in the ventricular septum, mimicking hypertrophic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/1,9,10\">",
"     1,9,10",
"    </a>",
"    ]. Dynamic left ventricular outflow tract obstruction can occur but is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2726667\">",
"    <span class=\"h3\">",
"     Small vessel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small vessel disease may manifest as purpura, claudication, or angina. The presence of periorbital purpura, often occurring with coughing, sneezing, or very minor trauma, suggests capillary involvement and its presence in a patient with unexplained heart failure strongly suggests amyloidosis, almost always of the AL type. Leg or jaw claudication are suggestive of vascular amyloidosis and may occur in conjunction with angina [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The involved vessels are typically small and intramyocardial; as a result, coronary angiography is usually normal or shows only minor abnormalities as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2726688\">",
"    <span class=\"h3\">",
"     Syncope and sudden death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope or presyncope is common in patients with cardiac amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/14\">",
"     14",
"    </a>",
"    ]. The presence of exertional syncope is particularly ominous, as it may represent an inability to augment cardiac output. It is associated with a high mortality in the three months after the initial event, often due to sudden cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/14\">",
"     14",
"    </a>",
"    ]. Multiple additional factors may contribute to syncope. These include postural or exertional hypotension due to excessive diuresis or autonomic neuropathy.",
"   </p>",
"   <p>",
"    Interestingly, ventricular arrhythmias appear to be an infrequent cause of syncope, possibly because the amyloid heart reacts poorly to hypoperfusion and any tachyarrhythmia severe enough to cause loss of consciousness is usually fatal. Observational data suggest that implantable cardioverter-defibrillator (ICD) therapy may not prolong survival in patients with amyloid cardiomyopathy, probably because the majority of sudden cardiac deaths are due to electromechanical dissociation rather than a potentially reversible ventricular arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23958?source=see_link&amp;anchor=H16788171#H16788171\">",
"     \"Treatment of amyloid cardiomyopathy\", section on 'Implantable cardioverter-defibrillator'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2731037\">",
"    <span class=\"h3\">",
"     Conduction system disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite widespread involvement of the conduction system, high-degree atrioventricular block is an unusual feature in AL amyloidosis, and symptomatic sinus node dysfunction appears uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/16\">",
"     16",
"    </a>",
"    ]. In contrast, progressive conduction system disease often occurs in the TTR amyloidoses (both senile and familial) and pacemaker implantation is often required.",
"   </p>",
"   <p>",
"    The conduction system is often affected in all forms of amyloid heart disease. Although the sinus node may be most often involved pathologically [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/17\">",
"     17",
"    </a>",
"    ], abnormal electrophysiologic function appears to be most common in the His-Purkinje system. Patients with AL amyloidosis may have progressive conduction disease, the severity of which may not be apparent from the surface electrocardiogram. This was illustrated in a study of 25 patients with AL amyloidosis involving the heart undergoing electrophysiologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/18\">",
"     18",
"    </a>",
"    ]. Sinus and atrioventricular nodal function were preserved in most patients, but infra-His conduction times were usually prolonged, as 23 and 12 patients had HV intervals greater than 55 and 80 msec, respectively. Prolongation of the HV interval may not be suspected clinically if the QRS is narrow on the ECG. Prolongation of the HV interval was the sole independent predictor of subsequent sudden death but prolongation of the HV interval may not be suspected since the QRS is often narrow on the ECG.",
"   </p>",
"   <p>",
"    However, the role of screening for these abnormalities is uncertain since limited clinical experience suggests that pacemaker or implantable cardioverter-defibrillator (ICD) implantation often fails to prevent sudden cardiac death, which in many cases is probably due to electromechanical dissociation related to the severe myocardial dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2726702\">",
"    <span class=\"h3\">",
"     Pericardial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid deposits in the pericardium may occasionally result in a pericardial effusion, which may rarely produce cardiac tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Because of the increased stiffness of the atrial and ventricular walls and the high filling pressures in both ventricles, the classical echocardiographic signs of cardiac tamponade, such as right atrial and right ventricular compression, may be absent so that a high degree of suspicion of cardiac tamponade should be entertained in a patient with a moderate or large pericardial effusion associated with amyloid heart disease and heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2726709\">",
"    <span class=\"h3\">",
"     Thromboembolism and stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with amyloid cardiomyopathy, particularly those with AL amyloidosis or atrial fibrillation, are at risk for cardiac thromboembolism. Amyloid infiltrates the atria as well as the ventricles and may cause atrial dysfunction, resulting in electromechanical dysfunction of the atrium during sinus rhythm which can predispose to atrial thrombi.",
"   </p>",
"   <p>",
"    A report of 116 autopsy or explanted cardiac amyloidosis cases identified intracardiac thrombus, predominantly in the atrium, in 33 percent of amyloid hearts (and none in 46 control hearts) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/21\">",
"     21",
"    </a>",
"    ]. Although AL subjects were younger and had less atrial fibrillation than those with other types of amyloidosis, the AL group had a significantly higher rate of intracardiac thrombus (51 versus 16 percent) and fatal embolic events (26 versus 8 percent). The presence of both atrial fibrillation and AL amyloidosis was associated with an extremely high risk for thromboembolism (odds ratio 55, 95% CI 8.1-1131). Other risk factors for thromboembolism included left ventricular diastolic dysfunction, increased right ventricular wall thickness, and faster heart rates, the latter presumably representing a compensatory response to a low stroke volume.",
"   </p>",
"   <p>",
"    The risk of ischemic stroke in patients with amyloidosis is not well defined. In a series of forty patients with primary amyloidosis and ischemic stroke evaluated at the Mayo Clinic, ischemic stroke was the initial presentation of amyloidosis in 13 (33 percent), preceding a pathologic diagnosis of amyloidosis by a mean of 9.6 months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/22\">",
"     22",
"    </a>",
"    ]. The majority of patients (70 percent) had cardioembolic strokes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2010208\">",
"    <span class=\"h3\">",
"     Peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathic signs such as numbness, paresthesia, pain, orthostatic hypotension, and bowel or bladder dysfunction are frequently prominent in patients with AL or mutant TTR amyloidosis. Carpal tunnel syndrome is seen in some patients with AL, senile systemic amyloidosis, or TTR mutations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H14#H14\">",
"     \"An overview of amyloidosis\", section on 'Neurologic abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2553095\">",
"    <span class=\"h2\">",
"     Type-specific findings and course",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2010147\">",
"    <span class=\"h3\">",
"     Age at onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual age of onset of symptoms varies among the various types of amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients with AL cardiac amyloidosis typically present at age &ge;40 years. Patients with senile cardiac amyloidosis typically present at age &ge;60 years, and most commonly &gt;70 years. Various transthyretin mutations are associated with various ages of onset (ranging from 30 to 70 years) and differing risks of cardiomyopathy as discussed below. (See",
"    <a class=\"local\" href=\"#H2731422\">",
"     'TTR mutation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2010302\">",
"    <span class=\"h3\">",
"     Type-specific course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated AL amyloidosis carries a poor prognosis, which varies depending on the predominant organ involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/24\">",
"     24",
"    </a>",
"    ]. When the heart is involved, the prognosis of an untreated patient is particularly poor. In contrast to AL amyloidosis, familial and senile amyloidoses are typically associated with milder clinical manifestations, slower progression, and better prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/7,24-26\">",
"     7,24-26",
"    </a>",
"    ]. This distinction was illustrated in a comparison of 36 patients with amyloid heart disease: 24 with AL amyloidosis and 12 with familial (mostly ATTR) amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/24\">",
"     24",
"    </a>",
"    ]. Although the two groups had similar echocardiographic findings, the one-year survival rates free of cardiac transplantation were 38 and 92 percent, respectively, and all deaths were cardiac (",
"    <a class=\"graphic graphic_figure graphicRef68010 \" href=\"UTD.htm?21/28/21965\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Similar findings were noted in a study of 18 randomly selected patients with AL amyloidosis that involved the heart and 18 with senile systemic TTR amyloidosis and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/26\">",
"     26",
"    </a>",
"    ]. Although the patients with AL amyloidosis were younger and had a lesser degree of thickening of the left ventricle, median survival was much shorter (11 versus 75 months). The difference in outcome in these studies could not be explained by the degree of amyloid infiltration of the myocardium as assessed by echocardiography and led to speculation that the rapid progression of heart failure in AL amyloidosis is due to a toxic effect of circulating light chains on a myocardium already damaged by amyloid deposition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27259717\">",
"    <span class=\"h3\">",
"     AL cardiac amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;AL amyloidosis is a plasma cell dyscrasia usually involving one or more organ systems. Common presentations of AL amyloidosis include nephrotic syndrome, hepatomegaly, peripheral neuropathy, macroglossia, purpura (including periorbital purpura, known as raccoon eyes), and bleeding diathesis. While none of these features is pathognomonic for AL amyloidosis, periorbital purpura and macroglossia in a patient with amyloidosis strongly suggest AL amyloidosis rather than another type. Cardiac involvement is present in at least 50 percent of patients and is the predominant manifestation of the disease in about 20 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/8,27\">",
"     8,27",
"    </a>",
"    ]. However, cardiac amyloidosis is rarely the sole manifestation of the disease, occurring in isolation in only 4 percent in a series of 232 patients with cardiac AL amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=see_link&amp;anchor=H863317#H863317\">",
"     \"Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Heart failure in AL amyloidosis is often more difficult to adequately treat than in TTR amyloidosis, as diuretic and ACE-inhibitor use may be limited by hypotension or renal hypoperfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23958?source=see_link\">",
"     \"Treatment of amyloid cardiomyopathy\"",
"    </a>",
"    .) Proteinuria may contribute to the edema and amyloid infiltration of the liver may occasionally contribute to hepatomegaly, although this is uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27260123\">",
"    <span class=\"h3\">",
"     ATTR cardiac amyloidosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2731422\">",
"    <span class=\"h4\">",
"     TTR mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloidosis due to a TTR mutation is an autosomal dominant disease, with a high degree of penetrance with most mutations. Single substitutions in an amino acid of TTR can render it unstable, resulting in a tendency to misfold and produce amyloid, which commonly infiltrates the myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/28\">",
"     28",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    The clinical manifestations vary, depending upon the particular substitution, but result either in neuropathy, cardiomyopathy, or both. These associations are discussed elsewhere but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=see_link&amp;anchor=H3#H3\">",
"     \"Genetic factors in the amyloid diseases\", section on 'Transthyretin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the most common mutations is a substitution of methionine for valine at codon 30 (Val30Met). This mutation is common in endemic areas such as Portugal, northern Sweden, and Japan, and most often presents with a lower extremity sensorimotor peripheral neuropathy (known as familial amyloid polyneuropathy). Although cardiac involvement occurs and echocardiographic manifestations may not be distinguishable from AL amyloidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/24,25,29\">",
"       24,25,29",
"      </a>",
"      ], these patients generally have much less severe myocardial disease and better survival than those with AL amyloidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      There appears to be a bimodal age of onset in this mutation, with early onset (third and fourth decade) presenting with peripheral neuropathy and minimal cardiac infiltration except for conduction system disease and late onset disease (sixth decade) presenting predominantly as an infiltrative amyloid cardiomyopathy. Age of onset and risk of cardiomyopathy also differs in various endemic and nonendemic settings [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, the Thr60Ala mutation, first described in the Appalachian region of the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/31\">",
"       31",
"      </a>",
"      ], and other less common mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/32,33\">",
"       32,33",
"      </a>",
"      ] are associated with a severe infiltrative cardiomyopathy, often with minimal neuropathy. Individuals with THr60Ala typically present at 50 to 60 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/30,34\">",
"       30,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The most common hereditary ATTR amyloid cardiomyopathy is the Val122Ile mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/35-38\">",
"       35-38",
"      </a>",
"      ]. This mutation, which is present in over 3.5 percent of the African-American and Afro-Caribbean population, is associated with a late-onset amyloid cardiomyopathy characterized by progressive severe heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/35,39,40\">",
"       35,39,40",
"      </a>",
"      ]. It should be suspected in any patient of African descent over the age of 50 who has unexplained left wall thickening on the echocardiogram and heart failure or echocardiographic evidence of diastolic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/41\">",
"       41",
"      </a>",
"      ]. A common mistake is to attribute ventricular wall thickening in these patients to hypertensive heart disease, but the degree of LV thickening (commonly &gt;15 mm) is usually disproportionate to the degree of hypertension and right sided signs of heart failure (uncommon in hypertensive heart disease) are frequently present due to concomitant right ventricular infiltration. Although the penetrance of disease caused by this mutation is unknown, it is almost certainly underdiagnosed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2731473\">",
"    <span class=\"h4\">",
"     Wild-type TTR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wild&ndash;type TTR causes the disease known as senile systemic amyloidosis. Amyloid deposits are frequently found in the hearts of elderly patients at autopsy, both in the atrium (where they are usually derived from atrial natriuretic peptide) and the ventricle (where they are most commonly derived from wild-type TTR). In the overwhelming majority of cases, these deposits are of no clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/42\">",
"     42",
"    </a>",
"    ]. However, there is an association between atrial amyloidosis and atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 136 cases of cardiac amyloidosis in individuals over 60 years old from a series of 52,370 autopsies, the prevalence of ventricular amyloid deposition increased with age and was higher among blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/35\">",
"     35",
"    </a>",
"    ]. The prevalence in the 70- to 79-year age group was 1.6 percent among blacks and 0.1 percent among whites and in those 90 years of age and older the rates were 8.2 percent of blacks and 2.7 percent of whites. Among all autopsied individuals over 60 years old, the incidence of cardiac amyloidosis was 1.6 percent among blacks, 0.42 percent in non-Hispanic whites, and 0.13 percent in Mexican Hispanics [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/44\">",
"     44",
"    </a>",
"    ]. A genetic cause for the higher prevalence of cardiac amyloid in blacks is discussed above. (See",
"    <a class=\"local\" href=\"#H2731422\">",
"     'TTR mutation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, in a small proportion of patients, the ventricular deposition is massive, resulting in cardiomegaly and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/45\">",
"     45",
"    </a>",
"    ]. The term senile cardiac amyloidosis is best reserved for these cases, since it is associated with a typical echocardiographic appearance and clinical course. Senile cardiac amyloidosis may be the most common form of amyloidosis in the United States. It almost exclusively affects elderly men (35 of 36, with a mean age of 73 in two reports) and is characterized by an infiltrative cardiomyopathy with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/26,46\">",
"     26,46",
"    </a>",
"    ]. Wild-type TTR may also be deposited in the lungs, hence the term \"senile systemic amyloidosis\" rather than senile cardiac amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/47\">",
"     47",
"    </a>",
"    ]. However, the lung deposition is clinically insignificant and the clinical picture is heart failure. Although patients with senile cardiac amyloidosis are older and have a greater degree of left ventricular thickening than those with cardiac AL amyloidosis, heart failure is much easier to control and there is a much slower rate of disease progression than in AL amyloidosis (median survival 75 versus 11 months in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/26\">",
"     26",
"    </a>",
"    ]. Carpal tunnel syndrome occurs in a substantial minority of patients but, unlike other forms of amyloidosis, clinically significant disease in other organs is generally absent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link\">",
"     \"An overview of amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2728998\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27260747\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination may reveal a variety of findings in patients with cardiac amyloidosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The jugular venous pressure is frequently markedly elevated, and the upper level may be missed unless the patient is also examined sitting upright.",
"     </li>",
"     <li>",
"      Hypertension is very uncommon, even in a patient with a prior history of hypertension. Hypotension may be present (systolic BP &lt;100 mmHg). This may be caused by a low cardiac output or by inappropriate peripheral vasodilation. Orthostatic hypotension, when present, suggests significant concomitant autonomic neuropathy and blood pressure should always be checked with the patient supine, seated, and standing [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The heart sounds are usually normal, although a right-sided third heart sound is occasionally heard when the right ventricle is severely affected. A fourth heart sound, which coincides with atrial systole, is unusual since atrial infiltration with amyloid causes atrial dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"       \"Auscultation of heart sounds\"",
"      </a>",
"      .) Amyloidosis rarely causes significant valve disease, but a murmur of tricuspid or mitral regurgitation is occasionally heard.",
"     </li>",
"     <li>",
"      Examination of the abdomen frequently reveals hepatomegaly due to congestion, and ascites may be present if heart failure is severe. Splenomegaly is rare and peripheral edema may be profound.",
"     </li>",
"     <li>",
"      The eyelids should be examined carefully for purpura, as periorbital purpura with heart failure is virtually pathognomonic of cardiac amyloidosis (almost invariably of the AL type).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27260754\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although low voltage in the limb leads is one of the most common ECG abnormalities in AL cardiac amyloidosis (occurring in approximate 50 percent), it is less common in the other forms of cardiac amyloidosis, being reported in about 25 percent of patients with familial disease and in about 40 percent of patients with senile cardiac amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/7,23,24,46,51,52\">",
"     7,23,24,46,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest reported ECG series of 127 patients with biopsy proven AL amyloidosis seen at the Mayo Clinic, the two most common abnormalities were low voltage and a pseudoinfarct pattern, which were seen in 46 and 47 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/52\">",
"     52",
"    </a>",
"    ]. Other findings included first degree AV block in 21 percent, nonspecific intraventricular conduction delay in 16 percent, second or third degree AV block in 3 percent, atrial fibrillation or flutter in 20 percent, and ventricular tachycardia in 5 percent. Electrocardiographic criteria for left ventricular hypertrophy were present in 16 percent, but some of these patients had a history of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/52\">",
"     52",
"    </a>",
"    ]. The LVH criteria were limited almost exclusively to precordial leads, sometimes with low-voltage limb leads.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2731030\">",
"    <span class=\"h1\">",
"     NONINVASIVE TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2553779\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is the initial noninvasive test of choice to diagnose cardiac amyloidosis (",
"    <a class=\"graphic graphic_movie graphicRef78037 \" href=\"UTD.htm?41/31/42481\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61904 \" href=\"UTD.htm?36/40/37507\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef64330 \" href=\"UTD.htm?43/47/44787\">",
"     movie 3",
"    </a>",
"    ). The various types of amyloid cardiomyopathy produce indistinguishable echocardiographic findings. Increased left ventricular wall thickness with evidence of diastolic dysfunction is the earliest echocardiographic abnormality, and right ventricular diastolic dysfunction can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More advanced disease is associated with the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive left ventricular wall thickening results in a nondilated or small LV cavity, with systolic impairment and restrictive physiology occurs with more advanced disease [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. Left ventricular wall thickening is generally symmetric. Disproportionate amyloid accumulation in the ventricular septum is uncommon [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/1,9,10\">",
"       1,9,10",
"      </a>",
"      ] and dynamic left ventricular outflow tract obstruction is rare [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The atria become enlarged and immobile, and thickening of the mitral and aortic valve leaflets and atrial septum may be noted.",
"     </li>",
"     <li>",
"      Pericardial effusion is often present. While this is usually small, clinically insignificant moderate or large effusions with cardiac tamponade have been described.",
"     </li>",
"     <li>",
"      Increased right ventricular wall thickness and right ventricular enlargement can also be seen [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The pulmonary artery systolic pressure, as estimated from the peak velocity of the tricuspid valve regurgitant jet, may indicate moderate pulmonary hypertension (estimated pulmonary artery pressure of 40 to 50 mmHg.) This is almost invariably secondary to the markedly elevated left ventricular diastolic pressure and does not indicate primary pulmonary hypertension or cor pulmonale.",
"     </li>",
"     <li>",
"      Doppler evaluation of transmitral blood flow velocity shows a restrictive filling pattern with striking E dominance and a short deceleration time (",
"      <a class=\"graphic graphic_waveform graphicRef72146 \" href=\"UTD.htm?31/45/32470\">",
"       waveform 1",
"      </a>",
"      ). The transmitral Doppler A wave may be reduced because of the restrictive pathophysiology, or because of impaired atrial contraction due to amyloid infiltration of the atrium. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=see_link\">",
"       \"Echocardiographic evaluation of left ventricular diastolic function\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Amyloid cardiomyopathy is associated with dissociation between short- and long-axis systolic function. Tissue Doppler or strain rate imaging shows impairment in long-axis contraction even when the left ventricular ejection fraction is within normal range [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/56\">",
"       56",
"      </a>",
"      ]. The degree of long-axis dysfunction is far greater than seen in conditions associated with true left ventricular hypertrophy such as hypertrophic cardiomyopathy or aortic stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. A typical pattern characterized by severe impairment of basal longitudinal (and basal radial) strain with preserved strain in the apical segments is typical, and is rarely seen in other diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Amyloid infiltration of the heart results in increased echogenicity. This was originally described as a \"granular, sparkling\" appearance of the myocardium (",
"      <a class=\"graphic graphic_movie graphicRef61904 \" href=\"UTD.htm?36/40/37507\">",
"       movie 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/51,59,60\">",
"       51,59,60",
"      </a>",
"      ]. However, \"sparkling\" myocardium is an insensitive indicator of amyloidosis, as only a minority of patients (eg, 26 to 36 percent) have this pattern and this finding has limited specificity (probably less than the 71 to 81 percent rates observed in referred populations) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/61\">",
"       61",
"      </a>",
"      ]. In addition, changes in echocardiographic technology such as tissue harmonic imaging enhance the appearance of myocardium generally and thus have rendered this finding less noticeable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140704\">",
"    <span class=\"h3\">",
"     Thrombus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracardiac thrombus is common in cardiac amyloidosis as demonstrated by echocardiography as well as pathologic examination. (See",
"    <a class=\"local\" href=\"#H2726709\">",
"     'Thromboembolism and stroke'",
"    </a>",
"    above.) In a retrospective study of 156 patients with cardiac amyloidosis who underwent transesophageal echocardiography, 58 intracardiac thrombi were identified in 42 patients (27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/62\">",
"     62",
"    </a>",
"    ]. Most of the 58 thrombi were in the left (n = 32) or right (n = 10) atrial appendage and only three thrombi were detected by transthoracic echocardiography. AL amyloid patients had intracardiac thrombus more frequently than patients with other types (predominantly TTR) (35 versus 18 percent). This was despite AL patients being younger and having less atrial fibrillation. Atrial fibrillation, poor left ventricular diastolic function, and lower left atrial appendage emptying velocity were independently associated with increased risk for intracardiac thrombosis, whereas anticoagulation at the time of the echocardiogram was associated with a significantly decreased risk.",
"   </p>",
"   <p>",
"    Based on these data and the autopsy data described above showing a very high prevalence of intracardiac thrombi, it is reasonable to assume that a patient with cardiac amyloidosis and an embolic event has a cardiac source. In such a case, transesophageal echocardiography may not be necessary to aid in the decision to initiate anticoagulation. As a corollary, the finding of a diminutive transmitral A wave on transthoracic echocardiography in a patient with cardiac amyloidosis may be an adequate reason to initiate anticoagulation even in the absence of a prior embolus. Selective use of transesophageal echocardiography is suggested in such patients to guide the need for prophylactic anticoagulation, looking not only for the presence of intracardiac thrombi, but also for high risk features such as very low left atrial appendage Doppler velocities even in the absence of a thrombus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1397433\">",
"    <span class=\"h2\">",
"     Voltage-to-mass ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular thickening due to amyloid infiltration may be misdiagnosed on echocardiography as left ventricular hypertrophy. However, unlike true left ventricular hypertrophy, left ventricular thickening in cardiac amyloidosis is associated with a decrease in electrocardiographic voltage.",
"   </p>",
"   <p>",
"    This combination of increased ventricular mass with reduced electrocardiographic voltage is unique to infiltrative cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/51,63,64\">",
"     51,63,64",
"    </a>",
"    ]. Other conditions resulting in low ECG voltage (tamponade, pericardial effusion, emphysema) are not associated with increased heart mass, while conditions associated with increased mass (hypertension, hypertrophy) are usually associated with normal or increased ECG voltage (",
"    <a class=\"graphic graphic_figure graphicRef75294 \" href=\"UTD.htm?11/17/11550\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective study compared the voltage-to-mass ratio to other diagnostic tests in patients with cardiac amyloidosis, predominantly due to AL amyloid [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/64\">",
"     64",
"    </a>",
"    ]. The ratio was more sensitive than electrocardiography, two-dimensional echocardiography alone, or nuclear scanning. In another report, the combination of low voltage on ECG and an interventricular septal thickness &gt;1.98 cm detected amyloidosis with a sensitivity and specificity of 72 and 91 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2554149\">",
"    <span class=\"h2\">",
"     Cardiovascular magnetic resonance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular magnetic resonance (CMR) imaging can provide evidence strongly suggestive of amyloid cardiomyopathy, particularly a distinctive pattern of global left ventricular late gadolinium enhancement (LGE) rarely seen in other cardiomyopathies. However, gadolinium contrast is contraindicated in patients with moderate to severe kidney disease. (See",
"    <a class=\"local\" href=\"#H140912\">",
"     'Caution with kidney disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a series of 35 patients with histologically confirmed cardiac amyloidosis, 29 (83 percent) had a pattern of global transmural or global subendocardial LGE [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/65\">",
"     65",
"    </a>",
"    ]. Suboptimal nulling despite use of multiple inversion times was seen in three patients and focal patchy LGE was seen in two patients. Atrial uptake of gadolinium is also commonly seen.",
"   </p>",
"   <p>",
"    CMR appears to be more sensitive for cardiac amyloid deposition than echocardiography, as CMR late gadolinium enhancement (LGE) may be seen in patients with amyloidosis with normal left ventricular wall thicknesses. Preliminary studies of the predictive value of LGE in patients with suspected cardiac amyloidosis have yielded sensitivities of 86 and 88 percent and specificities of 86 and 90 percent. [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The extent of LGE correlated with serum B-type natriuretic peptide (BNP) levels in two series [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/65,67\">",
"     65,67",
"    </a>",
"    ]. The presence of LGE predicted mortality risk in patients with amyloid cardiomyopathy in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/66\">",
"     66",
"    </a>",
"    ] but not in others [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    LGE and 99mTc-DPD scintigraphy may have similar sensitivity in detecting early amyloid cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/70\">",
"     70",
"    </a>",
"    ]. Among 16 patients with TTR familial amyloid polyneuropathy, six had cardiac 99mTc-DPD tracer uptake and LGE and 10 had no cardiac tracer uptake and no LGE. The pattern of LGE was focal in four patients, diffuse in one patient, and subendocardial circumferential in the only patient with signs of heart failure. (See",
"    <a class=\"local\" href=\"#H2554716\">",
"     'Nuclear imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    T2-weighted imaging may also be helpful. A study of 36 patients with amyloid cardiomyopathy and 48 healthy controls found that a hypointense signal on T2-weighted CMR imaging was an independent predictor of shorter survival [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/68\">",
"     68",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H140912\">",
"    <span class=\"h3\">",
"     Caution with kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with moderate to severe kidney disease, gadolinium administration has been associated with the rare occurrence of the potentially severe, and sometimes fatal, syndrome of nephrogenic systemic fibrosis. Therefore, gadolinium contrast-enhanced CMR should be avoided in patients with moderate to severely impaired renal function. Since many patients with amyloidosis have impaired renal function due either to the renal amyloidosis or low cardiac output, the use of gadolinium is relatively contraindicated in many patients with suspected amyloid cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2554716\">",
"    <span class=\"h2\">",
"     Nuclear imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technetium (Tc) pyrophosphate imaging was described as a potential diagnostic test for cardiac amyloidosis in the early 1980s. Although initial reports described increased cardiac uptake of Tc in patients with amyloid heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/71-73\">",
"     71-73",
"    </a>",
"    ], later studies found positive scans in less than 20 percent of patients with known cardiac amyloidosis, casting doubt on the sensitivity of this technique [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/64,74\">",
"     64,74",
"    </a>",
"    ]. These early studies were done at a time when precise typing of amyloidosis was unavailable, and when SPECT imaging was uncommonly used.",
"   </p>",
"   <p>",
"    A potential role for Tc imaging has emerged specifically in identification of TTR amyloidosis. Imaging with 99mTc-DPD, an isotope available in Europe, may distinguish between AL and transthyretin-related cardiac amyloidosis. In an initial report, cardiac uptake of 99mTc-DPD was present in all 15 patients with TTR amyloidosis (ATTR) compared to none of the 10 patients with AL amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/75\">",
"     75",
"    </a>",
"    ]. In a later study of 63 patients with ATTR, myocardial uptake of 99mTc-DPD was present in all 40 patients with amyloid cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/76\">",
"     76",
"    </a>",
"    ]. Tracer uptake was also present in 4 of 23 ATTR patients without echocardiographic evidence of cardiomyopathy; all four had amyloid infiltration on endomyocardial biopsy. The",
"    <span class=\"nowrap\">",
"     heart/whole",
"    </span>",
"    body retention value was a predictor of adverse prognosis. Although imaging with 99mTc-DPD is not available in the US, initial experience with Tc pyrophosphate imaging using SPECT shows a high sensitivity of this technique for diagnosing TTR amyloid cardiomyopathy, similar to the experience with 99mTc-DPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2554723\">",
"    <span class=\"h2\">",
"     Electrophysiologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, patients with amyloid cardiomyopathy are at risk for conduction system disease leading to pacemaker dependence and general indications for cardiac pacing should be applied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a specific role for routine electrophysiologic testing is patients with amyloid cardiomyopathy has not been established. Although electrophysiologic abnormalities (prolonged HV interval) appear to be common in AL amyloidosis, and a prolonged HV interval is an predictor of sudden death, it is unclear whether device therapy based upon electrophysiologic findings is beneficial. (See",
"    <a class=\"local\" href=\"#H2731037\">",
"     'Conduction system disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The utility of signal-averaged ECG (SAECG) in cardiac amyloidosis has not been established, although one report suggested that a SAECG may be helpful in detecting myocardial involvement. In a report of 133 patients with AL amyloidosis, late potentials on the SAECG were significantly more frequent in patients with echocardiographic evidence of cardiac amyloidosis (31 versus 9 percent in those with normal echocardiograms) and were independently predictive of an increased risk of sudden cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4391?source=see_link\">",
"     \"Clinical applications of the signal-averaged electrocardiogram: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27261444\">",
"    <span class=\"h2\">",
"     BNP and N-terminal pro-BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum B-type natriuretic peptide (BNP) concentrations are increased in patients with heart failure. The prohormone, pro-BNP, is cleaved during processing to yield equal amounts of the active hormone and the inactive N-terminal peptide (N-terminal pro-BNP), which is also increased in patients with heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevation in serum BNP in patients with AL amyloidosis is a marker of cardiac involvement that may be identified before onset of clinical heart failure. In one series, BNP values were significantly elevated in patients with AL amyloidosis with cardiac involvement seen on the echocardiogram [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/78\">",
"     78",
"    </a>",
"    ]. The elevations in serum BNP were similar in those with and without clinical evidence of heart failure (583 and 557",
"    <span class=\"nowrap\">",
"     pg/mL),",
"    </span>",
"    suggesting that amyloid-induced regional myocardial stress, caused by local myocyte deformation, may be a mechanism of BNP elevation in these patients in addition to the usual method of increased wall stress due to elevated ventricular filling pressure.",
"   </p>",
"   <p>",
"    BNP and N-terminal pro-BNP are elevated with any cause of heart failure and hence are of no diagnostic value in distinguishing amyloidosis from other causes of cardiomyopathy. However, elevated levels do appear to have prognostic value in AL amyloidosis as discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=see_link&amp;anchor=H863317#H863317\">",
"     \"Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Monoclonal paraprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a serum or urine monoclonal paraprotein in the setting of a typical echocardiogram is suggestive of AL amyloidosis, but it alone does not firmly establish the diagnosis. This was illustrated in a series of 350 patients initially diagnosed as having AL amyloidosis based on clinical and laboratory findings and the absence of a family history [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/79\">",
"     79",
"    </a>",
"    ]. In this series, 34 patients (10 percent) had a mutant gene for an amyloidogenic protein; eight of these patients had low serum concentrations of a monoclonal protein (less than 0.2",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    probably due to an unrelated monoclonal gammopathy of undetermined significance (MGUS), incorrectly suggesting AL amyloid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=see_link\">",
"     \"Genetic factors in the amyloid diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This observation illustrates the importance of excluding non-plasma cell related types of amyloidosis in patients with cardiac amyloidosis, particularly when the clinical features are not typical for AL amyloidosis. Such patients include older males with clinically isolated cardiac involvement and a small monoclonal gammopathy who may have senile cardiac amyloid and unrelated MGUS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10949908\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac amyloidosis should be considered in any adult with unexplained heart failure and an echocardiogram showing increased wall thickness with a nondilated left ventricular cavity, particularly when associated with low voltage on electrocardiography. &nbsp;(",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78406 \" href=\"UTD.htm?24/46/25312\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef78037 \" href=\"UTD.htm?41/31/42481\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef61904 \" href=\"UTD.htm?36/40/37507\">",
"     movie 2",
"    </a>",
"    ). As discussed above, symptoms may include dyspnea and edema as well as presyncope, syncope, and angina. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical presentation'",
"    </a>",
"    above.) The presence of proteinuria, hepatomegaly disproportionate to the degree of heart failure, or neuropathy are additional clinical clues that strongly suggest systemic amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/1,80\">",
"     1,80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link\">",
"     \"An overview of amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An approach to establishing the diagnosis and typing of amyloidosis is shown in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef79767 \" href=\"UTD.htm?14/51/15152\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27261359\">",
"    <span class=\"h2\">",
"     Tissue biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cardiac amyloidosis is confirmed either by demonstrating amyloid deposits on endomyocardial biopsy (",
"    <a class=\"graphic graphic_picture graphicRef64630 \" href=\"UTD.htm?9/56/10122\">",
"     picture 1",
"    </a>",
"    ) or, in patients with appropriate cardiac findings, by demonstrating amyloid deposits on histologic examination of a biopsy from other tissues (eg, abdominal fat pad, rectum, or kidney). Subcutaneous aspiration of abdominal fat will stain positive for amyloidosis in &gt;70 percent of patients with AL amyloidosis, but is subject to false positive staining in laboratories who do not routinely stain this tissue. Bone marrow biopsy should be a standard test in the initial work up of suspected AL amyloidosis, as it demonstrates evidence of a plasma cell dyscrasia in &gt;80 percent of patients and shows amyloid deposits in 60 percent",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/81\">",
"     81",
"    </a>",
"    ]. In addition, an occasional patient will have a very high plasma cell burden (&gt;50 percent cellularity), indicating co-existent multiple myeloma.",
"   </p>",
"   <p>",
"    If a patient has a typical noninvasive appearance of cardiac amyloidosis and a positive biopsy for amyloid from a noncardiac site, there is no need to pursue an endomyocardial biopsy. However, if cardiac biopsy is needed, it can generally be performed safely in skilled hands. In two retrospective studies, myocardial biopsy was positive in 40 of 41 patients, suggesting that this procedure is highly sensitive in properly selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H20#H20\">",
"     \"An overview of amyloidosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Microscopic examination of the myocardium shows amorphous hyaline deposits that are predominantly seen in the extracellular space. On electron microscopy, these are seen to be composed of non-branching fibrils. The fibrils bind Congo red (leading to green birefringence under polarized light), thioflavine T (producing an intense yellow-green fluorescence), and sulfated Alcian blue (producing a green color) (",
"    <a class=\"graphic graphic_picture graphicRef64630 \" href=\"UTD.htm?9/56/10122\">",
"     picture 1",
"    </a>",
"    ). Electron microscopic examination shows straight and unbranching fibrils. Immunofluorescence microscopy can be used to identify the type of protein subunit in many cases (",
"    <a class=\"graphic graphic_picture graphicRef75254 \" href=\"UTD.htm?35/29/36306\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/84,85\">",
"     84,85",
"    </a>",
"    ], but this technique is not 100 percent sensitive or specific and in equivocal cases the more accurate technique of laser microdissection followed by mass spectrometry of amyloid deposits (currently performed only at specialized centers) is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H139244\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of amyloid heart disease includes various causes of left ventricular hypertrophy including hypertensive heart disease, hypertrophic cardiomyopathy, Fabry disease, mitochondrial cardiomyopathy, and various other causes of restrictive cardiomyopathy such as infiltration with metastatic cancer, and idiopathic restrictive cardiomyopathy (",
"    <a class=\"graphic graphic_table graphicRef64479 \" href=\"UTD.htm?17/63/18429\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74268 \" href=\"UTD.htm?8/42/8876\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/10/23722/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link&amp;anchor=H7#H7\">",
"     \"Definition and classification of the cardiomyopathies\", section on 'Hypertrophic cardiomyopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40137?source=see_link\">",
"     \"Clinical features and diagnosis of Fabry disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23207?source=see_link\">",
"     \"Idiopathic restrictive cardiomyopathy\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left ventricular hypertrophy caused by hypertensive heart disease or hypertrophic cardiomyopathy or Fabry disease is usually associated with increased or normal ECG voltage in contrast to amyloid cardiomyopathy, which is associated with reduced electrocardiographic voltage. (See",
"      <a class=\"local\" href=\"#H1397433\">",
"       'Voltage-to-mass ratio'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=see_link\">",
"       \"Definition and pathogenesis of left ventricular hypertrophy in hypertension\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=see_link\">",
"       \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40137?source=see_link\">",
"       \"Clinical features and diagnosis of Fabry disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Echocardiographic characteristics such as diffuse increased echogenicity, valve thickening, and thickened interatrial septum help differentiate amyloid cardiomyopathy from other causes of left ventricular hypertrophy or restrictive cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H2553779\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Characteristic cardiovascular magnetic resonance findings (eg, global left ventricular late gadolinium enhancement) strongly suggest cardiac amyloidosis and are not expected in other causes of left ventricular hypertrophy or restrictive cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H2554149\">",
"       'Cardiovascular magnetic resonance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12693614\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amyloid cardiomyopathy is caused by infiltration of the heart by amyloidogenic proteins including monoclonal light chains in AL amyloidosis, mutated transthyretin in familial ATTR amyloidosis, and wild-type transthyretin in senile systemic amyloidosis. AA amyloidosis is a rare complication of chronic inflammatory diseases and is rarely associated with cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H165325929\">",
"       'Types of amyloidosis that may involve the heart'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac amyloidosis should be considered in adults with unexplained heart failure and an echocardiogram showing increased wall thickness with a nondilated left ventricular cavity, particularly in the absence of a history of hypertension or if the electrocardiographic voltage is normal or low. Additional manifestations include presyncope, syncope, angina, stroke, and peripheral neuropathy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2731030\">",
"       'Noninvasive testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10949908\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of heart failure plus heavy proteinuria, periorbital purpura, or hepatomegaly disproportionate to the degree of heart failure strongly suggests AL amyloidosis. (See",
"      <a class=\"local\" href=\"#H27259717\">",
"       'AL cardiac amyloidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiographic findings in amyloid cardiomyopathy include increased thickness of the ventricular walls (which may or may not be associated with increased echogenicity) as well as thickened valve leaflets and interatrial septum. Diastolic dysfunction and reduction in longitudinal systolic function precedes reduction in left ventricular ejection fraction. Atrial dysfunction is frequently present and may be associated with appendage thrombi even in the absence of a history of atrial fibrillation. (See",
"      <a class=\"local\" href=\"#H2553779\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While cardiovascular magnetic resonance (CMR) findings are often helpful in supporting the diagnosis of amyloid cardiomyopathy, a definitive diagnosis always requires tissue (myocardial or other) confirmation. (See",
"      <a class=\"local\" href=\"#H10949908\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An approach to further evaluation of patients with cardiac amyloidosis including typing is presented in the algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef79767 \" href=\"UTD.htm?14/51/15152\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10949908\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/1\">",
"      Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/2\">",
"      Dubrey SW, Cha K, Simms RW, et al. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol 1996; 77:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/3\">",
"      Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001; 104:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/4\">",
"      Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004; 94:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/5\">",
"      Benson MD. The hereditary amyloidoses. Best Pract Res Clin Rheumatol 2003; 17:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/6\">",
"      Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/7\">",
"      Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/8\">",
"      Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011; 97:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/9\">",
"      Sedlis SP, Saffitz JE, Schwob VS, Jaffe AS. Cardiac amyloidosis simulating hypertrophic cardiomyopathy. Am J Cardiol 1984; 53:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/10\">",
"      M&ouml;rner S, Hellman U, Suhr OB, et al. Amyloid heart disease mimicking hypertrophic cardiomyopathy. J Intern Med 2005; 258:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/11\">",
"      Philippakis AA, Falk RH. Cardiac amyloidosis mimicking hypertrophic cardiomyopathy with obstruction: treatment with disopyramide. Circulation 2012; 125:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/12\">",
"      Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 2000; 109:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/13\">",
"      Al Suwaidi J, Velianou JL, Gertz MA, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med 1999; 131:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/14\">",
"      Chamarthi B, Dubrey SW, Cha K, et al. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol 1997; 80:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/15\">",
"      Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008; 5:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/16\">",
"      Mathew V, Olson LJ, Gertz MA, Hayes DL. Symptomatic conduction system disease in cardiac amyloidosis. Am J Cardiol 1997; 80:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/17\">",
"      Ridolfi RL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients. Am J Med 1977; 62:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/18\">",
"      Reisinger J, Dubrey SW, Lavalley M, et al. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol 1997; 30:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/19\">",
"      Brodarick S, Paine R, Higa E, Carmichael KA. Pericardial tamponade, a new complication of amyloid heart disease. Am J Med 1982; 73:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/20\">",
"      Navarro JF, Rivera M, Ortu&ntilde;o J. Cardiac tamponade as presentation of systemic amyloidosis. Int J Cardiol 1992; 36:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/21\">",
"      Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007; 116:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/22\">",
"      Zubkov AY, Rabinstein AA, Dispenzieri A, Wijdicks EF. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology 2007; 69:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/23\">",
"      Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009; 120:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/24\">",
"      Dubrey SW, Cha K, Skinner M, et al. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997; 78:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/25\">",
"      Gertz MA, Kyle RA, Thibodeau SN. Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period. Mayo Clin Proc 1992; 67:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/26\">",
"      Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005; 165:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/27\">",
"      Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med 2000; 45:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/28\">",
"      Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/29\">",
"      Ogiwara F, Koyama J, Ikeda S, et al. Comparison of the strain Doppler echocardiographic features of familial amyloid polyneuropathy (FAP) and light-chain amyloidosis. Am J Cardiol 2005; 95:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/30\">",
"      Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010; 7:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/31\">",
"      Benson MD, Wallace MR, Tejada E, et al. Hereditary amyloidosis: description of a new American kindred with late onset cardiomyopathy. Appalachian amyloid. Arthritis Rheum 1987; 30:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/32\">",
"      Booth DR, Tan SY, Hawkins PN, et al. A novel variant of transthyretin, 59Thr-- Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family [see comments]. Circulation 1995; 91:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/33\">",
"      Lim A, Prokaeva T, Connor LH, et al. Identification of a novel transthyretin Thr59Lys/Arg104His. A case of compound heterozygosity in a Chinese patient diagnosed with familial transthyretin amyloidosis. Amyloid 2002; 9:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/34\">",
"      Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012; 33:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/35\">",
"      Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997; 336:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/36\">",
"      Falk RH. The neglected entity of familial cardiac amyloidosis in African Americans. Ethn Dis 2002; 12:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/37\">",
"      Connors LH, Doros G, Sam F, et al. Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy. Amyloid 2011; 18 Suppl 1:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/38\">",
"      Connors LH, Prokaeva T, Lim A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009; 158:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/39\">",
"      Jacobson DR, Ittmann M, Buxbaum JN, et al. Transthyretin Ile 122 and cardiac amyloidosis in African-Americans. 2 case reports. Tex Heart Inst J 1997; 24:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/40\">",
"      Jacobson DR, Pastore R, Pool S, et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 1996; 98:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/41\">",
"      Jacobson D, Tagoe C, Schwartzbard A, et al. Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men. Am J Cardiol 2011; 108:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/42\">",
"      Cornwell GG 3rd, Westermark P. Senile amyloidosis: a protean manifestation of the aging process. J Clin Pathol 1980; 33:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/43\">",
"      R&ouml;cken C, Peters B, Juenemann G, et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002; 106:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/44\">",
"      Buck FS, Koss MN, Sherrod AE, et al. Ethnic distribution of amyloidosis: an autopsy study. Mod Pathol 1989; 2:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/45\">",
"      Falk RH. Senile systemic amyloidosis: are regional differences real or do they reflect different diagnostic suspicion and use of techniques? Amyloid 2012; 19 Suppl 1:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/46\">",
"      Kyle RA, Spittell PC, Gertz MA, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996; 101:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/47\">",
"      Westermark P, Bergstr&ouml;m J, Solomon A, et al. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 2003; 10 Suppl 1:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/48\">",
"      Freeman R. Autonomic peripheral neuropathy. Lancet 2005; 365:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/49\">",
"      Dubrey S, Pollak A, Skinner M, Falk RH. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 1995; 74:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/50\">",
"      Modesto KM, Dispenzieri A, Cauduro SA, et al. Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. Eur Heart J 2005; 26:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/51\">",
"      Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004; 43:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/52\">",
"      Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005; 95:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/53\">",
"      Klein AL, Hatle LK, Burstow DJ, et al. Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990; 15:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/54\">",
"      Klein AL, Hatle LK, Taliercio CP, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990; 16:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/55\">",
"      Patel AR, Dubrey SW, Mendes LA, et al. Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol 1997; 80:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/56\">",
"      Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003; 107:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/57\">",
"      Engvall C, Henein M, Holmgren A, et al. Can myocardial strain differentiate hypertrophic from infiltrative etiology of a thickened septum? Echocardiography 2011; 28:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/58\">",
"      Baccouche H, Maunz M, Beck T, et al. Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography. Echocardiography 2012; 29:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/59\">",
"      Siqueira-Filho AG, Cunha CL, Tajik AJ, et al. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 1981; 63:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/60\">",
"      Eriksson P, Eriksson A, Backman C, et al. Highly refractile myocardial echoes in familial amyloidosis with polyneuropathy. A correlative echocardiographic and histopathological study. Acta Med Scand 1985; 217:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/61\">",
"      Selvanayagam JB, Hawkins PN, Paul B, et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007; 50:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/62\">",
"      Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009; 119:2490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/63\">",
"      Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 1982; 49:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/64\">",
"      Simons M, Isner JM. Assessment of relative sensitivities of noninvasive tests for cardiac amyloidosis in documented cardiac amyloidosis. Am J Cardiol 1992; 69:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/65\">",
"      Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010; 3:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/66\">",
"      Austin BA, Tang WH, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2009; 2:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/67\">",
"      Ruberg FL, Appelbaum E, Davidoff R, et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 2009; 103:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/68\">",
"      Wassmuth R, Abdel-Aty H, Bohl S, Schulz-Menger J. Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis. Eur Radiol 2011; 21:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/69\">",
"      Maceira AM, Prasad SK, Hawkins PN, et al. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008; 10:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/70\">",
"      Di Bella G, Minutoli F, Mazzeo A, et al. MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy. AJR Am J Roentgenol 2010; 195:W394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/71\">",
"      Sobol SM, Brown JM, Bunker SR, et al. Noninvasive diagnosis of cardiac amyloidosis by technetium-99m-pyrophosphate myocardial scintigraphy. Am Heart J 1982; 103:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/72\">",
"      Wizenberg TA, Muz J, Sohn YH, et al. Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am Heart J 1982; 103:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/73\">",
"      Falk RH, Lee VW, Rubinow A, et al. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am J Cardiol 1983; 51:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/74\">",
"      Gertz MA, Brown ML, Hauser MF, Kyle RA. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med 1987; 147:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/75\">",
"      Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/76\">",
"      Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011; 4:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/77\">",
"      Dubrey SW, Bilazarian S, LaValley M, et al. Signal-averaged electrocardiography in patients with AL (primary) amyloidosis. Am Heart J 1997; 134:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/78\">",
"      Nordlinger M, Magnani B, Skinner M, Falk RH. Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol 2005; 96:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/79\">",
"      Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002; 346:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/80\">",
"      Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/81\">",
"      Swan N, Skinner M, O'Hara CJ. Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases. Am J Clin Pathol 2003; 120:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/82\">",
"      Pellikka PA, Holmes DR Jr, Edwards WD, et al. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Intern Med 1988; 148:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/83\">",
"      Arbustini E, Merlini G, Gavazzi A, et al. Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients. Am Heart J 1995; 130:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/84\">",
"      Arbustini E, Verga L, Concardi M, et al. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002; 9:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/85\">",
"      O'Hara CJ, Falk RH. The diagnosis and typing of cardiac amyloidosis. Amyloid 2003; 10:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/10/23722/abstract/86\">",
"      Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114:4957.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4942 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23722=[""].join("\n");
var outline_f23_10_23722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12693614\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H165325929\">",
"      TYPES OF AMYLOIDOSIS THAT MAY INVOLVE THE HEART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2009885\">",
"      General manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2728666\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2726667\">",
"      - Small vessel disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2726688\">",
"      - Syncope and sudden death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2731037\">",
"      - Conduction system disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2726702\">",
"      - Pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2726709\">",
"      - Thromboembolism and stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2010208\">",
"      - Peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2553095\">",
"      Type-specific findings and course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2010147\">",
"      - Age at onset",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2010302\">",
"      - Type-specific course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27259717\">",
"      - AL cardiac amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27260123\">",
"      - ATTR cardiac amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2731422\">",
"      TTR mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2731473\">",
"      Wild-type TTR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2728998\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27260747\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27260754\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2731030\">",
"      NONINVASIVE TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2553779\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H140704\">",
"      - Thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1397433\">",
"      Voltage-to-mass ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2554149\">",
"      Cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H140912\">",
"      - Caution with kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2554716\">",
"      Nuclear imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2554723\">",
"      Electrophysiologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27261444\">",
"      BNP and N-terminal pro-BNP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Monoclonal paraprotein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10949908\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27261359\">",
"      Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H139244\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12693614\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4942\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4942|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?14/51/15152\" title=\"algorithm 1\">",
"      Diagnosis cardiac amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4942|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/46/25312\" title=\"diagnostic image 1\">",
"      M mode amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4942|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/28/21965\" title=\"figure 1\">",
"      Survival cardiac amyloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/17/11550\" title=\"figure 2\">",
"      Voltage mass relation amyloid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4942|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/56/10122\" title=\"picture 1\">",
"      Cardiac amyloidosis Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/29/36306\" title=\"picture 2\">",
"      Amyloid AA IF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4942|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?41/31/42481\" title=\"movie 1\">",
"      Cardiac amyloidosis short axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?36/40/37507\" title=\"movie 2\">",
"      Cardiac amyloidosis four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?43/47/44787\" title=\"movie 3\">",
"      Cardiac amyloidosis parasternal long axis echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4942|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/63/18429\" title=\"table 1\">",
"      ESC 2008 CM familial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/42/8876\" title=\"table 2\">",
"      ESC 2008 CM nonfamilial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4942|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/45/32470\" title=\"waveform 1\">",
"      Doppler diastolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4391?source=related_link\">",
"      Clinical applications of the signal-averaged electrocardiogram: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40137?source=related_link\">",
"      Clinical features and diagnosis of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=related_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=related_link\">",
"      Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=related_link\">",
"      Genetic factors in the amyloid diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23207?source=related_link\">",
"      Idiopathic restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=related_link\">",
"      Pathogenesis of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=related_link\">",
"      Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23958?source=related_link\">",
"      Treatment of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_10_23723="Torg system classfication";
var content_f23_10_23723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Torg system for classification of stress fractures of the proximal 5th metatarsal",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type I fractures (early)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No intramedullary sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sharp, well-delineated fracture line",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimal cortical hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fracture line generally involves only the lateral cortex (ie, does not extend to opposite cortex).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type II fractures (delayed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Widened fracture line that usually involves both cortices",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Periosteal new bone adjacent to fracture line is prominent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Some intramedullary sclerosis present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Type III fractures (non-union)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wide fracture line with periosteal new bone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete obliteration of medullary canal at the fracture site by sclerotic bone",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Strayer, SM, Reece, SG, Petrizzi, MJ. Fractures of the Proximal Fifth Metatarsal. American Family Physician 1999; 59: 9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23723=[""].join("\n");
var outline_f23_10_23723=null;
var title_f23_10_23724="Geriatric weight chart";
var content_f23_10_23724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Weight charts for older persons",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Height (inches)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Weight (pounds)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        60-69 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        70-79 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        80-89 years&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        127-151&nbsp;",
"       </td>",
"       <td>",
"        121-153",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        131-163",
"       </td>",
"       <td>",
"        125-155",
"       </td>",
"       <td>",
"        119-148",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        135-163",
"       </td>",
"       <td>",
"        127-157",
"       </td>",
"       <td>",
"        120-150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        140-173",
"       </td>",
"       <td>",
"        129-161",
"       </td>",
"       <td>",
"        128-152",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        144-179",
"       </td>",
"       <td>",
"        130-164",
"       </td>",
"       <td>",
"        125-155",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        148-184",
"       </td>",
"       <td>",
"        133-167",
"       </td>",
"       <td>",
"        128-158",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        153-190",
"       </td>",
"       <td>",
"        136-170",
"       </td>",
"       <td>",
"        130-162",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        158-196",
"       </td>",
"       <td>",
"        139-174",
"       </td>",
"       <td>",
"        133-165",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        162-201",
"       </td>",
"       <td>",
"        142-178",
"       </td>",
"       <td>",
"        137-169",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        167-207",
"       </td>",
"       <td>",
"        146-182",
"       </td>",
"       <td>",
"        140-175",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        172-213",
"       </td>",
"       <td>",
"        149-186",
"       </td>",
"       <td>",
"        144-180",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        177-219",
"       </td>",
"       <td>",
"        154-190",
"       </td>",
"       <td>",
"        148-187",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Any patient falling below these weights should be considered nutritionally at risk; multiply height by 2.54 to convert to cm, and divide weight by 2.2 to convert to kg.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23724=[""].join("\n");
var outline_f23_10_23724=null;
var title_f23_10_23725="Coyne spoon";
var content_f23_10_23725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Coyne spoon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 156px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23725=[""].join("\n");
var outline_f23_10_23725=null;
var title_f23_10_23726="RT alone or with chemo early HL";
var content_f23_10_23726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Radiotherapy alone or with chemotherapy in stage I-II Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The risk of failure by treatment in a meta-analysis of thirteen trials of stage I-II Hodgkin lymphoma combined for radiation therapy (RT) alone or with multiagent chemotherapy. Combined therapy was associated with a significantly lower failure rate for recurrent disease at five and ten years (16 versus 33 percent at ten years) (left panel) but no improvement in overall survival (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Specht, L, Gray, RG, Clarke, MJ, Peto, R, J Clin Oncol 1998; 16:830.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23726=[""].join("\n");
var outline_f23_10_23726=null;
var title_f23_10_23727="DIP examination";
var content_f23_10_23727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examination of DIP flexion and extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To evaluate flexion (A) and extension (B) of the distal interphalangeal (DIP) joint, immobilize the&nbsp;proximal interphalangeal (PIP)&nbsp;and metacarpophalangeal (MCP)&nbsp;joints of the finger being examined, and then have the patient actively flex and extend the DIP joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_10_23727=[""].join("\n");
var outline_f23_10_23727=null;
